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A B S T R A C T
Background
Tobacco smoking is the leading preventable cause of death worldwide, which makes it essential to stimulate smoking cessation. The
financial cost of smoking cessation treatment can act as a barrier to those seeking support. We hypothesised that provision of financial
assistance for people trying to quit smoking, or reimbursement of their care providers, could lead to an increased rate of successful quit
attempts. This is an update of the original 2005 review.
Objectives
The primary objective of this review was to assess the impact of reducing the costs for tobacco smokers or healthcare providers for using or
providing smoking cessation treatment through healthcare financing interventions on abstinence from smoking. The secondary objectives
were to examine the eLects of diLerent levels of financial support on the use or prescription of smoking cessation treatment, or both,
and on the number of smokers making a quit attempt (quitting smoking for at least 24 hours). We also assessed the cost eLectiveness of
diLerent financial interventions, and analysed the costs per additional quitter, or per quality-adjusted life year (QALY) gained.
Search methods
We searched the Cochrane Tobacco Addiction Group Specialised Register in September 2016.
Selection criteria
We considered randomised controlled trials (RCTs), controlled trials and interrupted time series studies involving financial benefit
interventions to smokers or their healthcare providers, or both.
Data collection and analysis
Two reviewers independently extracted data and assessed the quality of the included studies. We calculated risk ratios (RR) for individual
studies on an intention-to-treat basis and performed meta-analysis using a random-eLects model.
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Main results
In the current update, we have added six new relevant studies, resulting in a total of 17 studies included in this review involving financial
interventions directed at smokers or healthcare providers, or both.
Full financial interventions directed at smokers had a favourable eLect on abstinence at six months or longer when compared to no
intervention (RR 1.77, 95% CI 1.37 to 2.28, I2 = 33%, 9333 participants). There was no evidence that full coverage interventions increased
smoking abstinence compared to partial coverage interventions (RR 1.02, 95% CI 0.71 to 1.48, I2 = 64%, 5914 participants), but partial
coverage interventions were more eLective in increasing abstinence than no intervention (RR 1.27 95% CI 1.02 to 1.59, I2 = 21%, 7108
participants). The economic evaluation showed costs per additional quitter ranging from USD 97 to USD 7646 for the comparison of full
coverage with partial or no coverage.
There was no clear evidence of an eLect on smoking cessation when we pooled two trials of financial incentives directed at healthcare
providers (RR 1.16, CI 0.98 to 1.37, I2 = 0%, 2311 participants).
Full financial interventions increased the number of participants making a quit attempt when compared to no interventions (RR 1.11, 95%
CI 1.04 to 1.17, I2 = 15%, 9065 participants). There was insuLicient evidence to show whether partial financial interventions increased quit
attempts compared to no interventions (RR 1.13, 95% CI 0.98 to 1.31, I2 = 88%, 6944 participants).
Full financial interventions increased the use of smoking cessation treatment compared to no interventions with regard to various
pharmacological and behavioural treatments: nicotine replacement therapy (NRT): RR 1.79, 95% CI 1.54 to 2.09, I2 = 35%, 9455 participants;
bupropion: RR 3.22, 95% CI 1.41 to 7.34, I2 = 71%, 6321 participants; behavioural therapy: RR 1.77, 95% CI 1.19 to 2.65, I2 = 75%, 9215
participants.
There was evidence that partial coverage compared to no coverage reported a small positive eLect on the use of bupropion (RR 1.15, 95%
CI 1.03 to 1.29, I2 = 0%, 6765 participants). Interventions directed at healthcare providers increased the use of behavioural therapy (RR
1.69, 95% CI 1.01 to 2.86, I2 = 85%, 25820 participants), but not the use of NRT and/or bupropion (RR 0.94, 95% CI 0.76 to 1.18, I2 = 6%,
2311 participants).
We assessed the quality of the evidence for the main outcome, abstinence from smoking, as moderate. In most studies participants were
not blinded to the diLerent study arms and researchers were not blinded to the allocated interventions. Furthermore, there was not always
suLicient information on attrition rates. We detected some imprecision but we judged this to be of minor consequence on the outcomes
of this study.
Authors' conclusions
Full financial interventions directed at smokers when compared to no financial interventions increase the proportion of smokers who
attempt to quit, use smoking cessation treatments, and succeed in quitting. There was no clear and consistent evidence of an eLect on
smoking cessation from financial incentives directed at healthcare providers. We are only moderately confident in the eLect estimate
because there was some risk of bias due to a lack of blinding in participants and researchers, and insuLicient information on attrition rates.
P L A I N   L A N G U A G E   S U M M A R Y
Do interventions that reduce the cost of smoking cessation treatment increase quit rates, quit attempts or use of treatments?
Background
Interventions that reduce or cover the costs of smoking cessation medication and behavioural support could help smokers quit. We
reviewed the evidence about the eLects of financial interventions directed at smokers and healthcare providers on medication use, quit
attempts and successful quitting.
Study characteristics
We searched all relevant studies that involved financial interventions directed at smokers and healthcare providers. For smokers, the aim of
the healthcare financing interventions had to be to encourage the use of smoking cessation treatment or making successful quit attempts.
For interventions directed at healthcare providers, the intervention had to stimulate the healthcare provider to assist people with quitting
smoking, for example by prescribing smoking cessation treatment.
Key results
For the update of this review, we searched studies on the eLect of financial interventions on smoking cessation treatment and success in
September 2016. We found six new relevant studies, resulting in a total of 17 studies.
We found 15 studies directed at smokers. Covering all the costs of smoking cessation treatment for smokers (free treatment) when
compared to providing no financial benefits increased the number of smokers who attempted to quit (4 studies, 9065 participants), used
smoking cessation treatments (7 studies, 9455 participants), and succeeded in quitting (6 studies, 9333 participants).
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We found three studies directed at healthcare providers. The two studies that investigated the eLect of a financial intervention on quit
success (2311 participants) did not clearly show an increase in quit rates. Financial interventions directed at healthcare providers also did
not have an eLect on the use of smoking cessation medication (2 studies, 2311 participants). However, financial interventions did increase
the number of smokers who used smoking cessation counselling (3 studies, 25,820 participants).
Information on the costs of the intervention was available for eight studies (33,488 participants). The economic evaluation of the individual
studies showed that although the absolute diLerences in quitting were small, the costs per person successfully quitting were low or
moderate.
Quality of the evidence
We concluded that financial interventions directed at smokers increase the proportion of smokers who attempt to quit, use smoking
cessation treatments, and succeed in quitting. We did not detect a clear eLect on smoking cessation from financial incentives directed at
healthcare providers. This review has some limitations that aLect how confident we can be in the conclusions. The included studies varied
substantially in quality and in methods and design, which makes it diLicult to compare results.
Healthcare financing systems for increasing the use of tobacco dependence treatment (Review)
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Summary of findings for the main comparison.   Interventions directed at individuals: full financial coverage compared to no financial coverage for
increasing abstinence from smoking
Interventions directed at individuals: full financial coverage compared to no financial coverage for increasing abstinence from smoking
Patient or population: smokers
Setting: medical practises, companies, members of a health insurance company, outpatient respirology clinic
Intervention: full financial coverage for abstinence from smoking
Comparison: no coverage
Anticipated absolute effects* (95% CI)Outcomes
Risk with no coverage Risk with full financial cov-
erage
Relative effect
(95% CI)
№ of participants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Study populationAbstinence
from smoking
84 per 1000 149 per 1000
(115 to 192)
RR 1.77
(1.37 to 2.28)
9333
(6 RCTs)
⊕⊕⊕⊝
Moderate1,2
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence 
High quality: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect
1Downgraded one level because of risk of bias: all studies except for Hughes 1991 had a serious risk of bias.
2We rated Hughes 1991 and Twardella 2007 serious for imprecision, and Pakhale 2015 very serious for imprecision, however, we did not downgrade the evidence because these
studies were small and had a minor eLect on the outcome.
 
 
Summary of findings 2.   Interventions directed at healthcare providers compared to placebo for increasing the use of smoking cessation treatment
Interventions directed at healthcare providers compared to no interventions for increasing the use of smoking cessation treatment
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Patient or population: physicians and clinics from a multispecialty group practice
Setting: health clinics in the USA and group practices in Germany
Intervention: financial interventions directed at healthcare providers (pay for performance and direct payment)
Comparison: no financial intervention
Anticipated absolute effects* (95% CI)Outcomes
Risk with no interventions Risk with interventions directed
at healthcare providers
Relative effect
(95% CI)
№ of partici-
pants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Study populationAbstinence
from smoking
181 per 1000 209 per 1000
(177 to 247)
RR 1.16
(0.98 to 1.37)
2311
(2 RCTs)
⊕⊕⊕⊝
Moderate1
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence 
High quality: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect
1Downgraded one level because both studies were judged to be at serious risk of bias.
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B A C K G R O U N D
Tobacco smoking is a major risk factor for non-communicable
diseases. A range of interventions such as pharmacotherapy and
counselling are currently in use to treat nicotine dependence
(Aveyard 2007). Although the majority of smokers attempt to
quit unassisted (Edwards 2014), treatments are recommended,
as they can increase quit success (West 2000; Aveyard 2007;
Nides 2008; Lancaster 2017; Stead 2017). Existing management
strategies  for smoking cessation remain limited in eLectiveness
since a significant majority of smokers attempting to quit either fail
to quit or relapse aSer a successful quit (Foulds 2006; Mitrouska
2007; West 2015). Apart from counselling and pharmacotherapy,
strategies such as financial interventions may be useful to address
the problem in a multifaceted manner and increase cessation rates
(Coleman 2001; Benowitz 2008).
Regardless of scientific acceptability, treatment utilisation by
smokers and selection of treatment strategies by healthcare
providers and insurance companies are influenced by cost
considerations, as documented in non-experimental studies (Cox
1990; Gencarelli 2003; Briesacher 2007; Goto 2007; Hollenbeck
2011). As a result, costs and a variety of financial interventions
are becoming increasingly important considerations in medical
practice to improve patient outcomes and quality of service
(Cheung 1997; Peckham 2010; Van Herck 2010). For instance,
an international survey reported that in several countries a
larger proportion of physicians are likely to receive financial
incentives based on quality improvement targets: the percentage
of physicians provided with incentives was 89% in the UK; 81% in
the Netherlands; 70% in Italy; and 65% in Austria (Schoen 2009).
Despite their popularity, financial interventions are shown to have
at best weak or mixed impacts on service quality and patient
outcomes (Steel 2007; Peckham 2010; De Bruin 2011; Flodgren
2011; Ryan 2016). In a review of 128 studies that implemented
financial incentives in healthcare, Van Herck and colleagues
indicated that, for incentive schemes to be eLective, they need
to be applied to individuals or teams and have prior set targets
for quality and patient outcome improvements (Van Herck 2010).
Reviews also indicate that there is little or no information on the
cost-eLectiveness of these incentives (Van Herck 2010; De Bruin
2011; Scott 2011).
According to reports, smoking cessation treatments are highly cost
eLective compared to other, commonly implemented preventive
interventions, such as hypertension and cholesterol-lowering
treatments (Cheung 1997; Parrot 2004). In a systematic review of
the literature, Ronckers and colleagues reported that in spite of
lack of standardised reporting by the included studies, smoking
cessation treatments aimed at reducing smoking prevalence are
cost-eLective (Ronckers 2005).
In light of limited resources and the increasing cost of health care,
it is pertinent to examine the impact of financial interventions
provided to smokers and healthcare providers on treatment and
process-related outcomes such as smoking cessation service use.
We hypothesised that provision of financial assistance for smokers
trying to quit, or reimbursement of their healthcare providers,
could lead to an increased rate of quit attempts, utilisation of
smoking cessation treatments, and successful quitting. This review
evaluates financial interventions directed at individual smokers
regardless of whether they achieve cessation and also evaluates
financial interventions directed at healthcare providers. A separate
Cochrane Review evaluates competitions and incentives to reward
smokers who achieve cessation or abstinence in smoking cessation
schemes (Cahill 2015).
O B J E C T I V E S
The primary objective of this review was to assess the impact
of reducing the costs of providing or using smoking cessation
treatment by healthcare financing interventions on abstinence
from smoking. The secondary objectives were to examine the
eLects of diLerent levels of financial support on the use or
prescription of smoking cessation treatment, or both, and on
the number of smokers making a quit attempt (quitting smoking
for at least 24 hours). We also assessed the cost eLectiveness
of diLerent financial interventions, and analysed the costs per
additional quitter, or per quality-adjusted life year (QALY) gained.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered randomised controlled trials (RCTs), controlled trials
(CTs) and interrupted time series (ITS) studies. We included ITS
studies if they had at least three time points before and three aSer
the intervention, and if they had a clearly defined intervention
point.
Types of participants
We included those studies in which the study population consisted
of smokers or healthcare providers. We assessed the primary
and secondary objectives from either a smoker’s or a healthcare
provider’s perspective. For smokers, the aim of the healthcare
financing interventions had to be to encourage the use of
smoking cessation treatment and successful quit attempts. When
the intervention was directed towards healthcare providers, the
intervention had to aim to aLect the prescribing of smoking
cessation treatment or the smoking behaviour of the participants,
or both, by oLering assistance to quit smoking.
Types of interventions
We included trials that studied the eLects of healthcare financing
interventions directed at smokers or healthcare providers for
increasing the use of smoking cessation treatment (e.g. delivered
by government, healthcare insurance plans, or other institution-
arranged interventions).
We classified patient-centred financial interventions as:
• Health insurance coverage - changes to the level of benefit
available for smoking cessation treatments, including changes
to copayment or out-of-pocket payments made by people
receiving treatment.
• Direct coverage - changes to the direct cost to the smoker of
using smoking cessation treatment, for example by provision of
a prescription for free pharmacotherapy.
• Health insurance cost - changes to the premiums or user fees
paid for health insurance.
We defined healthcare provider-centred financing interventions
as:    
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• Salary - payment for a set number of working hours or sessions
per time unit.
• Capitation - a set amount of payment per patient for providing
specific care.
• Fee-for-service - payment for every item of service or unit of care
provided.
• Target payment (pay for performance, P4P) - payment only
made with respect to achievement of an agreed target.
• Fund holding- and organisation-level payment systems - which
can improve the working conditions within an organisation, and
can indirectly influence the salary of a healthcare provider.
We diLerentiated between healthcare financing interventions for
individual smokers and for healthcare providers. In patients,
for example, comparisons can be made between full financial
coverage and partial financial coverage. For healthcare providers,
a maximum target payment can be compared with no target
payment. There were no restrictions on the type of smoking
cessation treatment for which the financial benefit could be
oLered. This could include pharmacotherapy (e.g. nicotine
replacement therapy, varenicline or bupropion), behavioural
support, or a combination thereof. When the financial intervention
of a study was aimed at more than one type of smoking cessation
treatment, the eLect of the financial intervention could be spread
out over the diLerent types of products. Studies of financial
interventions that are aimed at more than one type of smoking
cessation treatment therefore cannot formally be compared with
studies that oLer coverage for only one product. This is the
reason for diLerentiating between partial and full interventions as
discussed in the next paragraph. As a result we focused on full and
partial financial interventions. As a smoker could use more than
one type of product, summing the use of the diLerent types of
smoking cessation treatment could overestimate the number of
smokers who used smoking cessation treatment.
We classified the patient-directed financial benefits as full,
partial or no intervention, based on theoretical and practical
considerations. We considered an intervention that covered the
cost of both pharmacotherapy and behavioural support to be a full
financial intervention. Full financing need not come from the trial.
If there were already existing provisions (e.g. insurance) for partial
coverage of smoking cessation treatment (pharmacotherapy or
behavioural support) and a trial’s intervention(s) complemented
this benefit by financing either a pharmacotherapy or behavioural
support leading to full coverage of smoking cessation treatment,
we classified it as a full-coverage intervention. In this case we
considered the control group to be partial financial intervention.
More specifically, if an intervention provided coverage for either
pharmacotherapy or behavioural support, we considered it partial
financial coverage. If a study involved gradations of partial financial
intervention, we considered the one with more benefits from the
trial’s perspective to be the intervention group while the group
receiving lesser benefits was the control group. If, in a given
study, a control group received neither trial-based nor already
existing financing arrangements for smoking cessation treatment,
we considered it a no-financing intervention. On these bases, we
employed further stratification depending on the availability of
study data. 
Types of outcome measures
We included studies when they used at least one of the following
outcome measures to describe the eLects of the intervention. The
primary outcome measure of this review was:
• abstinence from smoking. We included studies reporting
abstinence from smoking at least six months aSer the start
of the intervention, and we used the longest available follow-
up as the preferred outcome measure (SRNT 2002; Hughes
2003). Biochemically validated abstinence was preferred to self-
reported abstinence, and continuous or prolonged abstinence
was preferred to point-prevalence abstinence.
The secondary outcome measures were:
• number of participants making a quit attempt, defined as the
number of participants who attempted to quit at least once. A
quit attempt is defined as not having smoked for at least 24
hours.
• Use of smoking cessation treatment, defined as the number
of participants who reported having used smoking cessation
treatment or who were registered by healthcare providers
or medical insurance organisations as having used smoking
cessation treatment.
Economic Evaluation
To evaluate the cost eLectiveness of financial interventions for
smoking cessation treatment, we considered data from studies
that examined both cost and eLects and compared two or more
alternatives. The primary outcome measure of the economic
evaluation was smoking-related:
• costs per additional quitter.
The secondary outcome measure was:
• costs per quality-adjusted life year saved (QALY). This measure
of health outcome incorporates the eLect of an intervention on
both the length and the quality of life.
Search methods for identification of studies
We identified eligible studies for the current update by electronic
search of the Cochrane Tobacco Addiction Group Specialised
Register, limited to records added since April 2012. This Register
includes citations identified via highly sensitive searches for
potential reports of controlled trials and other evaluations of
interventions for smoking cessation and prevention. At the time
of the search on 1 September 2016, the Register included the
results of searches of the Cochrane Central Register of Controlled
trials (CENTRAL; 2016, issue 7) in the Cochrane Library; MEDLINE
(via OVID), to update 20160729, Embase (via OVID), to update
week 201639 and PsycINFO (via OVID) to update 20160725. See
the Tobacco Addiction Group Module in the Cochrane Library for
full search strategies and list of other resources searched. The
search strategy (Appendix 1) included MeSH and text terms related
to health care costs, health insurance coverage, reimbursement,
remuneration, incentives, salaries and fees.
There was no limitation on language. The Cochrane Tobacco
Addition Group's Information Specialist performed the register
search, and also prescreened retrieved records for relevance to the
topic.
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In order to retrieve unpublished studies, we contacted experts in
the field via a standardised email. We included unpublished studies
or abstracts only when suLicient data were available.
For the original review and first update, additional searches of
MEDLINE (Appendix 2) and Embase were conducted that combined
topic-related terms with the same smoking- and design-related
terms used in the regular searches for the Register. Since these
records are a subset of the records retrieved and screened during
regular searches we judged this no longer necessary.
The Cochrane Tobacco Addiction Group's glossary of smoking-
related terms can be found in Appendix 3.
Data collection and analysis
Selection of studies
Based on title, keywords and abstract, three reviewers (FB, GN, AAR)
each selected studies independently of each other by applying the
inclusion criteria to the studies identified by the literature search.
When there was any doubt whether to select a study or not, we
resolved it through discussion. Two reviewers (FB and GN) assessed
the full-paper versions of the selected studies in duplicate for each
study and independently of each other. If disagreements about
inclusion were not resolved by consensus, we arranged to consult
additional reviewers (DK and AAR).
Data extraction and management
Two reviewers (FB and GN) separately and independently extracted
data from the included studies, aSer which the extracted data were
compared and discussed. Any disagreements between the two
reviewers were resolved by discussion. We extracted the following
data.
• Methods: setting (location of care, country, and year of study)
and study design
• Participants and/or healthcare providers: method of
recruitment, inclusion criteria, characteristics of study
population (smoking status, age, gender and motivation to quit
smoking)
• Interventions: description of the intervention for each group
• Outcome measures: definition for each study of continuous
abstinence or point-prevalence abstinence, number of
participants making a quit attempt, prescription and use of
smoking cessation treatment
• Results: we extracted the findings of each study for pooling
Two reviewers (AAR and SE) extracted data concerning the
economic evaluations that we used to answer our secondary
objectives. We resolved any discrepancies by discussion. We
extracted the following data.
• Perspective and time horizon of the economic evaluation
• Direct costs: volume and value of costs of the use of smoking
cessation treatment, costs of consultations with healthcare
providers and overhead costs (no research costs)
• Indirect costs: volume and value of general medical care, lost
productivity, time and travel costs spent by participants visiting
healthcare providers
• Discounting and sensitivity analyses
• Results of the economic evaluations
Assessment of risk of bias in included studies
We assessed the risk of bias of the included studies using criteria
from Cochrane included in the Review Manager (RevMan) 5
soSware (Higgins 2011; RevMan 2014). The criteria have three levels
(low risk of bias, high risk of bias, unclear risk of bias) and the
judgement on each item could be complemented using quotes
from the study report and the raters’ comments. We rated the
following criteria: sequence generation; allocation concealment;
blinding of intervention; issues of incomplete data and loss to
follow-up; and other unclassified bias identified by the review
authors. We summarised findings from these criteria in Figure 1.
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Figure 1.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study
 
The reviewers assessing risk of bias were not blinded to the
authors, institution or journal title. Two reviewers (FB and GN)
independently rated the studies. We held a consensus meeting to
discuss and resolve disagreements between the two reviewers. If
a study did not contain suLicient information on methodological
criteria or the information was unclear, we contacted the study
authors for additional information.
Economic Evaluation
We assessed the quality of the economic evaluations using the
Consensus Health Economic Criteria (CHEC) list (Evers 2005).
As its name indicates, the CHEC list was produced based on
expert consensus. It consists of 19 items as listed in Appendix 4
and incorporates the following aspects: clearly described study
population (age, gender and educational level), a description of
the intervention and the alternatives, a well-defined research
question, an economic study design in which the costs and eLects
Healthcare financing systems for increasing the use of tobacco dependence treatment (Review)
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of two or more interventions are compared, a time horizon and
perspective of the evaluation, the identification of relevant costs
and consequences for each alternative, the measurement of costs
and consequences, appropriately valued cost and consequences,
the performance of an incremental analysis, the performance of
discounting and sensitivity analysis, the conclusions following
from the data reported, the generalisability of results, statement
of conflict of interest and appropriate discussion of ethical and
distributional issues. SE independently assessed the quality of the
economic evaluations. Items scored as 'yes' received one point.
Items scored as 'unclear' or 'no' received no points. We calculated
a total score by summing the score of the 19 items (range 0 to 19).
Measures of treatment e=ect
We used only intention-to-treat analyses. If the study did not
present an intention-to-treat analysis then we recalculated the
published data on an intention-to-treat basis. We counted all
dropouts and participants lost to follow-up as continuing smokers
or making no quit attempt or not having used smoking cessation
treatment. For each study outcome we calculated the risk ratio
(RR) and the corresponding 95% confidence interval (CI) as a
measure of intervention eLect. Since the outcomes (abstinence,
quit attempts and use of treatment) were favourable, a ratio greater
than unity indicates an outcome favouring financial intervention.
Where we calculated pooled eLects, we used a Mantel-Haenszel
method to estimate the RR using a random-eLects model. We
considered pooling when at least two trials assessed the eLects
of healthcare financing interventions and reported data on the
same outcome measure. We conducted a formal statistical test
for between-studies variance, and assessed whether the observed
variability in eLect sizes was greater than would be expected to
occur by chance (sampling error). We used the I2 statistic, given by
the formula ((Q-df)/Q)*100%, to investigate heterogeneity (where Q
represents Cochrane’s Chi2 statistic and df is the degree of freedom,
Higgins 2003). We considered a pooled analysis to have moderate
and high heterogeneity when the I2 statistic was more than 50% and
75% respectively.
Economic Evaluation
The transferability of cost estimates of diLerent economic
evaluations is mostly restricted by diLerences in setting. These
diLerences can be related to patient characteristics, incidence
of smoking-related diseases, availability of health resources,
variations in clinical practice, incentives to healthcare providers
and relative prices or costs (Drummond 2015). Pooling of the
diLerent economic evaluations is only permissible when there is no
interaction between the setting and the eLect of the intervention
on medical consumption (Drummond 2015). Where pooling was
allowed, the volumes of medical consumption, like the use of
smoking cessation treatment, were to be pooled and multiplied
with the pooled costs per unit consumption. The total costs
were calculated in US dollars (USD). When the cost estimates
of the diLerent economic evaluations were not transferable,
we presented cost data of the individual studies. When no
incremental ratios were presented, we calculated the incremental
cost eLectiveness ratios ourselves. First, we calculated the total
costs per group. We then divided the diLerence in costs between the
groups by the diLerence in number of quitters between the groups.
The authors of the studies involved checked the calculation. When
currencies other than USD were involved, we used the exchange
rates provided by study authors.
'Summary of findings' table
Following standard Cochrane methodology (Schünemann 2011),
we created 'Summary of findings' tables for our primary
outcome for interventions directed at smokers (Summary of
findings for the main comparison) and interventions directed at
healthcare providers (Summary of findings 2). This included a
GRADE evaluation of the quality of evidence, based on the five
standard considerations (study limitations, consistency of eLect,
imprecision, indirectness and publication bias) (Guyatt 2011).
R E S U L T S
Description of studies
Results of the search
We identified 3518 references using the search strategy described
above, of which 28 were identified from the Register search for
this update (for a PRISMA flow chart see Figure 2) (Moher 2009).
ASer we had removed duplicates, 23 studies remained, of which
six new studies were included in the current update (Patel 2010;
Papadakis 2011; Willemsen 2013, Jardin 2014; Selby 2014; Pakhale
2015) and 17 were listed as excluded, with reasons (see Excluded
studies table). With the six new studies added in this update, we
included a total of 17 studies in this review.
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Figure 2.   Prisma study flow diagram of studies included in most recent update of this review
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Figure 2.   (Continued)
 
Included studies
Full details of the 17 included studies are given in the
Characteristics of included studies table; we describe the main
features below.
Setting and design
Ten of the included studies were performed in the USA (Hughes
1991; Curry 1998; SchauLler 2001; Boyle 2002; Roski 2003; Halpin
2006; An 2008; Joyce 2008; Patel 2010; Jardin 2014). The others
were conducted in Canada (Papadakis 2011; Selby 2014; Pakhale
2015), the UK (Dey 1999), the Netherlands (Kaper 2006; Willemsen
2013 ) and Germany (Twardella 2007). Four studies were conducted
in co-operation with health insurance organisations (Curry 1998;
SchauLler 2001; Boyle 2002; Kaper 2006). Two studies were
conducted in family practices (Hughes 1991; Dey 1999), two in
an Ottawa hospital clinic (stroke prevention: Papadakis 2011,
respirology: Pakhale 2015) and one study was conducted in 40
clinics of a multi-speciality medical group practice (Roski 2003).
Of the seventeen included studies, eleven randomly assigned
the individual participants to the treatment group and one or
two control groups (Hughes 1991; Dey 1999; SchauLler 2001;
Roski 2003; Halpin 2006; Kaper 2006; Patel 2010; Papadakis 2011;
Jardin 2014; Selby 2014; Pakhale 2015) and three randomly
assigned medical practices (Twardella 2007; An 2008; Joyce
2008). Two studies (Curry 1998; Boyle 2002) were controlled
natural experiments with two and four diLerent benefit groups,
respectively. One study used a descriptive time-series analysis
(Willemsen 2013).
Participants
FiSeen studies were directed at individuals (Hughes 1991; Curry
1998; Dey 1999; SchauLler 2001; Boyle 2002; Halpin 2006; Kaper
2006; Twardella 2007; Joyce 2008; Patel 2010; Papadakis 2011;
Jardin 2014; Selby 2014; Willemsen 2013; Pakhale 2015). Sample
sizes of the included studies varied from 28 participants in
Papadakis 2011 to 7354 in Joyce 2008. All participants were at
least 18 years old. The age of the participants in the included
studies varied from a mean of 38 to more than 65 years. Six studies
included a general population of smokers (Curry 1998; SchauLler
2001; Halpin 2006; Kaper 2006; Patel 2010; Willemsen 2013. Dey
1999 and Selby 2014 included only smokers who were motivated to
quit. Half of the sample included in Boyle 2002 was motivated to
quit smoking. All of the participants in An 2008; Papadakis 2011 and
Pakhale 2015 were motivated to quit smoking in the next 30 days.
Participants in Hughes 1991 did not have to be motivated to quit
to participate in the study, but were allowed to withdraw from the
study aSer they were told that they would be randomly assigned
to diLerent price groups. Participants were voluntarily enrolled and
motivated to quit in Joyce 2008. Jardin 2014 included smokers not
wanting to quit in the next 30 days.
Three studies assessed the eLects of financial interventions
directed at healthcare providers (Roski 2003; Twardella 2007;
An 2008). Twardella 2007 involved both patient- and healthcare
provider-directed interventions. In the studies that involved
healthcare provider-directed interventions, patient behaviour was
measured using a baseline survey and a follow-up survey aSer six
months.
Interventions
Patient-directed interventions
Six studies investigated the eLect of changes to the level
of insurance coverage for smoking cessation treatment (Curry
1998; SchauLler 2001; Boyle 2002; Kaper 2006; Willemsen 2013;
Selby 2014). Nine studies investigated the eLect of changes to
the direct cost to the smoker of receiving treatment (Hughes
1991; Dey 1999; Halpin 2006; Twardella 2007; Joyce 2008; Patel
2010; Papadakis 2011; Jardin 2014; Pakhale 2015). Coverage was
oLered for four diLerent types of smoking cessation treatment:
nicotine replacement therapy (NRT), bupropion, varenicline and
behavioural support. Three studies each covered two types of
smoking cessation treatment: Boyle 2002 oLered coverage for
NRT (patches and gum) and bupropion, and Curry 1998 and
SchauLler 2001 covered NRT (patches and gum) and participation
in a behavioural programme. Kaper 2006; Halpin 2006; Twardella
2007 and Joyce 2008 covered three types of therapy: NRT
(patches, gum, sublingual tablets and lozenges), bupropion and
behavioural support. Papadakis 2011 and Selby 2014 covered NRT,
bupropion and also varenicline. In Pakhale 2015 participants were
oLered free telephone counselling and they received a USD 110
voucher for pharmacotherapy of their own choice. In Willemsen
2013 smokers could be reimbursed by their insurance company
for pharmacotherapy if they also engaged in (free) telephone
counselling. The treatment periods ranged from two weeks (Jardin
2014) to one year (Curry 1998; SchauLler 2001; Boyle 2002; Kaper
2006 Joyce 2008 and Selby 2014). The included studies also varied
in the extent of insurance coverage or treatment cost and the
comparisons made. Seven studies compared full coverage of the
cost of treatment with no coverage (Hughes 1991; SchauLler 2001;
Kaper 2006; Twardella 2007; Joyce 2008; Willemsen 2013; Pakhale
2015). Five studies reported the eLect of partial interventions as
compared to no financial intervention (Hughes 1991; Boyle 2002;
Papadakis 2011; Jardin 2014; Selby 2014). One study compared full
coverage of both behavioural treatment and NRT with a partial
benefit requiring a 50% co-payment for either behavioural or
NRT components (Curry 1998) and two studies investigated the
diLerences between a cost to the patient of USD 20, USD 6/USD 10
or USD 0 per box of nicotine gum (Hughes 1991; Patel 2010). Joyce
2008 provided four categories of benefit ranging from usual care to
benefits of pharmacotherapy and counselling.
Healthcare provider-directed interventions
Roski 2003 distributed printed versions of smoking cessation
guidelines to clinics in both the intervention and control group.
The intervention group clinics were eligible for payments for
reaching targets for registration of participants’ smoking status
and providing advice to quit. Twardella 2007 provided a tutorial
to general practitioners on how to conduct counselling and
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prescribe pharmacotherapy to help smokers; additionally, the
practitioners were provided with a financial remuneration of EUR
130 for each participant they treated and who was biochemically
confirmed to have quit at the end of six months' follow-up. An
2008 compared usual care and a pay-for-performance intervention
oLering USD 5000 for 50 quitline referrals. Pay-for-performance
clinics also received monthly updates on their referral numbers.
Outcomes
Abstinence from smoking aSer six months or more from the
start of the intervention was the primary and preferred outcome.
Boyle 2002 presented self-reported continuous (more than six
months) abstinence rates. The longest follow-up report comes
from Kaper 2006 in which biochemically validated continuous
abstinence was reported at 12 months, while Selby 2014 reported
biochemically validated continuous abstinence for weeks 26-52
and Twardella 2007 and Papadakis 2011 reported biochemically
validated continuous abstinence at six months' follow-up. Seven
studies presented self-reported point prevalence abstinence data
(Hughes 1991; Curry 1998; SchauLler 2001; Roski 2003; Halpin 2006;
Joyce 2008; Pakhale 2015). Three studies reported biochemically
validated point prevalence abstinence data (Patel 2010; Papadakis
2011; Selby 2014). In Hughes 1991, observers named by the
participants were asked to verify reported smoking status of
participants. Dey 1999 assessed abstinence from smoking at 14
weeks aSer the start of the reimbursement period and Jardin 2014
at 12 weeks; therefore, we did not include data from these studies
in the analysis of the eLects of reimbursement on abstinence rates.
Pakhale 2015 had problems with data collection and therefore
measured point prevalence abstinence at diLerent endpoints
between 26 and 52 weeks, with an average of 33 weeks aSer
baseline.
One of the secondary outcome measures was the number of
participants who made a quit attempt. Eight studies presented
data on this outcome (Hughes 1991; SchauLler 2001; Boyle 2002;
Halpin 2006; Kaper 2006; Papadakis 2011; Jardin 2014; Selby 2014).
The other secondary outcome measure was the self-reported use
or registered use of smoking cessation treatment. This was self-
reported in SchauLler 2001; Boyle 2002; Kaper 2006; Papadakis
2011; Jardin 2014 and Pakhale 2015, registered by a health
maintenance organisation in Curry 1998, and by the local pharmacy
in Hughes 1991; Dey 1999; Halpin 2006; An 2008 and Selby 2014.
Utilisation of smoking cessation services was reported by general
practitioners in Twardella 2007 and by telephone counsellors
in Papadakis 2011. Roski 2003 recorded self-reports by smokers
regarding the use of bupropion or NRT and/or any counselling
services. Willemsen 2013 used data on treatment enrolment
recorded by the national quit line. Patel 2010 only registered the
number of nicotine boxes acquired by participants and not actual
medication use.
Eight of the 17 included studies presented data on the costs
of the intervention, and compared the costs and eLects of the
intervention with one or two alternatives (Hughes 1991; Curry 1998;
SchauLler 2001; Halpin 2006; Kaper 2006; Twardella 2007; An 2008;
Joyce 2008). Most of the studies used a time horizon equal to
the duration of the intervention, and all used a third party payer
perspective, in which only the direct costs of the intervention were
presented. Curry 1998 also presented a user's perspective. The cost
eLectiveness ratio was presented in terms of costs per user who
quit smoking or costs per participant enrolled. No study presented
data in terms of quality-adjusted life years (QALY) saved. For Kaper
2006, additional information on outcomes on quit attempts, use of
treatment and cost were collected from two other related reports
(Kaper 2005a, Kaper 2006a).
Excluded studies
Of the 60 studies for which we assessed full reports for eligibility,
we excluded 45 (see Characteristics of excluded studies). Six studies
were research protocols without data (Courtney 2014; OstroL 2014;
Harter 2015; Bonevski 2016; Park 2016; NCT00962988). Although
NCT00962988 and OstroL 2014 had not yet been published at the
time of writing this review, we assessed them as probably relevant
and therefore registered as ongoing studies. The Characteristics
of excluded studies table summarises the reasons for exclusion.
Most excluded studies were not randomised controlled trials,
controlled trials or interrupted time series (ITS) studies (Alberg
2004; Cummings 2006). Oswald 1988 and Cox 1990 retrospectively
compared the outcomes of using free and purchased gum in a
non-randomised trial. Russos 1999; Parnes 2002 and Stone 2002
all used a cross-sectional design. Bailey 2016 was a cohort study
and Hamilton 2013 a systematic review. Fiore 2000, Coleman 2001,
Doescher 2002, Latts 2002, Ringen 2002, Solberg 2002, Amundson
2003, Chang 2008 and Weisman 2012 did not have a control group
and also did not use an ITS design. Land 2010 used an ITS design
but did not meet the required inclusion criterion of three measuring
points before and three aSer the intervention for the outcomes quit
attempts and quit success and we therefore excluded it. There were
other reasons for exclusion in addition to study design. Lave 1996
compared two diLerent financial systems in two diLerent settings,
and did not report data on the smoking status of the control group.
The financial intervention in nine studies (Curry 1991; Hovell 1996;
Russos 1999; Donatelle 2000; Pardell 2003; Volpp 2006; Kruse 2013;
McLeod 2015; Moskowitz 2016) was not directly related to the use
of smoking cessation treatment. Krist 2010 was excluded since
its intervention of free counselling was not directed specifically
at smoking but also at 'unhealthy' behaviours such as drinking
alcohol. Hays 1999 and Hockenberry 2012 were excluded because
they did not explicitly and directly assess the eLects of a financial
intervention. Shaw 2003 assessed the eLect of nicotine gum prices
on the use of gum and abstinence rates, and did not report the
number of participants using smoking cessation treatment or the
quit rate. We excluded Walsh 2012; Amemori 2013; Bardach 2013
and Verbiest 2013 because they did not measure relevant outcome
measures for this review. Fu 2016 was aimed at assessing the eLect
of proactive counselling and lacked a suitable control group.
Risk of bias in included studies
The summary results of our methodological assessment are
displayed in Figure 1.
Allocation
Ten studies stated that individual participants were randomly
allocated to the diLerent benefit groups (Hughes 1991; Dey
1999; SchauLler 2001; Halpin 2006; Kaper 2006; Patel 2010;
Papadakis 2011; Jardin 2014; Selby 2014; Pakhale 2015). Three
studies randomly allocated clinics to study conditions and then
identified smokers (Roski 2003; Twardella 2007; An 2008). One study
conducted randomisation based on the location or geography of
the primary care clinics (Joyce 2008). Although the exact method
for generating the randomisation sequence was generally not
reported, we classified all these 14 studies as having a low risk of
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bias for this part of the design. Three studies (Curry 1998; Boyle
2002 and Willemsen 2013) were not randomised trials and did not
involve experimental manipulation of conditions. Willemsen 2013
used a natural on-oL design in the entire Dutch population and
we classified it as having an unclear risk of bias. Boyle 2002 and
Curry 1998 made use of natural experiments in which diLerent
insured groups were receiving diLerent smoking cessation benefits.
This had the potential for bias due to diLerences between people
in diLerent benefit groups, and therefore we classified these two
studies as a having a high risk of bias.
Five studies reported allocation concealment with enough detail
to judge there to be a low risk of selection bias (Hughes 1991; Dey
1999; Papadakis 2011; Selby 2014; Pakhale 2015). Six studies did
not give enough information on allocation concealment procedure
and we therefore assessed them as having an unclear risk of bias
(SchauLler 2001; Halpin 2006; Jardin 2014; Patel 2010; An 2008; ).
We judged five studies to be at high risk of bias (Curry 1998; Boyle
2002; Kaper 2006; Twardella 2007; Joyce 2008). For Curry 1998
and Boyle 2002 allocation concealment was not directly applicable
because benefit groups were not experimentally manipulated, for
the other three studies, we judged allocation concealment to be
inadequate. For Willemsen 2013 allocation concealment was not
applicable because of its ITS design.
Blinding
Kaper 2006 blinded the participants in the control group to the
treatment available to the experimental group and evaluated the
success of the blinding and concluded that it was successful.
Therefore, this was the only study that we assessed as being at
low risk of bias. We judged three studies to be at unclear risk of
bias due to lack of information provided. We judged 13 studies
to be at high risk of bias because of incomplete) or no blinding
(An 2008; Boyle 2002; Curry 1998; Dey 1999; Halpin 2006; Hughes
1991; Joyce 2008; Pakhale 2015; Papadakis 2011; Roski 2003;
SchauLler 2001; Selby 2014; Twardella 2007). In Papadakis 2011
clinicians and participants were not blinded, but the research co-
ordinator conducting the outcome assessment was blind to group
allocation. Selby 2014 unblinded the investigator and participant
before deciding on the smoking cessation method to be used, but
both were blinded to the results of cotinine tests.
Incomplete outcome data
We assessed eight studies to be at low risk of attrition bias (Hughes
1991; Curry 1998; Halpin 2006; Kaper 2006; An 2008; Papadakis
2011; Jardin 2014; Pakhale 2015); the other studies we assessed
to be at high risk of attrition bias. In Boyle 2002 participants were
self-selected respondents to a survey so an ITT analysis was not
possible. In addition, the study authors did not account for 20%
'unusable sample' excluded from the analysis. Dey 1999 and Joyce
2008 had diLerent attrition rates in the experimental and control
groups, and did not provide an explanation for this diLerence, so
it was unclear whether attrition was at random or not. Patel 2010
reported significant diLerent attrition rates between experimental
groups. In Roski 2003 it was not reported how non-response or loss
to follow-up were handled in the analysis. SchauLler 2001 did not
provide suLicient information on missing data and did not report
an ITT. In Selby 2014 a higher proportion of the participants in the
control group discontinued the study because they were 'no longer
willing to participate'. The follow-up rate was less than 80% for all
the included studies except in Curry 1998; Halpin 2006; Twardella
2007 and Jardin 2014, which had higher rates. In Patel 2010 55%
of the participants in the control group compared to 13% in the
intervention group withdrew from the study. Five studies did not
address incomplete data (Dey 1999; SchauLler 2001; Boyle 2002;
Roski 2003; Twardella 2007). Hughes 1991; Halpin 2006; Kaper 2006;
Papadakis 2011; Jardin 2014 and Selby 2014 used an ITT analysis.
Other potential sources of bias
We classified six studies as being at high risk of another source of
bias (Dey 1999; Boyle 2002; Roski 2003; Kaper 2006; Willemsen 2013;
Pakhale 2015). In Boyle 2002; Kaper 2006 and Pakhale 2015 self-
reports of quitting or abstinence were not properly validated. Dey
1999 lacked power and reported only short-term abstinence. Roski
2003 reported a possible Hawthorne eLect on all clinics regardless
of randomisation status. A potential source of bias for the ITS
study of Willemsen 2013 is that the start of the reimbursement
period was accompanied by a large media campaign to encourage
smokers to apply for the free smoking cessation programme. We
judged eight studies to be at unclear risk of bias (Hughes 1991;
Curry 1998; SchauLler 2001; Halpin 2006; An 2008; Joyce 2008; Patel
2010; Papadakis 2011), for details see Characteristics of included
studies). There was no or unclear baseline comparability reported
with regard to important predictors such as smoking levels and
dependence, age, sex, income etc. in four studies (Hughes 1991;
Boyle 2002; Roski 2003; Joyce 2008). In Papadakis 2011 participants
in the intervention group reported smoking more cigarettes per
day and they also reported a higher self-eLicacy with quitting than
participants in the control group. Patel 2010 reported a higher mean
number of cigarettes smoked per day in the intervention group
and an unequal distribution of male/female participants across
intervention groups.
Quality of economic evaluation studies
The methodological quality assessment regarding the economic
evaluations is presented in Appendix 4. The score of the five studies
varied between 6 and 15 (out of a possible maximum of 19). In
only one study were all relevant costs identified, measured and
valued appropriately (Kaper 2006). For example, costs of visits
to healthcare providers were not measured, no contact times
were presented, the volumes of the use of smoking cessation
treatment were incomplete and the sources of cost valuation were
not described. Incremental analyses and sensitivity analyses were
not performed. Direct costs were not discounted, but this was
appropriate as the time frame of the cost analysis was less than
12 months. No statements of potential conflicts of interest were
presented.
E=ects of interventions
See: Summary of findings for the main comparison Interventions
directed at individuals: full financial coverage compared to
no financial coverage for increasing abstinence from smoking;
Summary of findings 2 Interventions directed at healthcare
providers compared to placebo for increasing the use of smoking
cessation treatment
To determine the general eLect of healthcare financing
interventions, we performed meta-analysis using a random-
eLects model. When only one study examined the eLects of an
intervention on a specific outcome, we presented the results of this
individual study graphically.
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The e=ect of financial interventions directed at smokers
Abstinence from smoking
In this section we report the eLect of financial interventions
directed at smokers on continuous and point prevalence
abstinence rates. The reported abstinence rates were stratified into
four diLerent intervention subgroups and the pooled eLect of each
of the financial benefit combinations is reported.
Full coverage versus no financial intervention 
Six studies reported the eLect of full versus no financial
intervention. Among these, two reported biochemically validated
continuous abstinence rates at six months (Twardella 2007) and
one year (Kaper 2006). The other studies reported six-month
(Hughes 1991; SchauLler 2001) and 12-month (Joyce 2008) self-
reported point prevalence abstinence, and abstinence between 26
and 52 weeks (Pakhale 2015), which we considered as six-month
abstinence. In all six studies the abstinence rate favoured the
intervention group, however, only SchauLler 2001; Kaper 2006 and
Joyce 2008 reached statistical significance. Upon pooling of the
six studies there was a statistically significant favourable eLect of
financial interventions on abstinence but with a moderate level
of heterogeneity (RR 1.77, 95% CI 1.37 to 2.28, I2 = 33%, 9333
participants) (Analysis 1.1).
Full coverage versus partial coverage interventions
Five studies reported the eLect of full compared to partial
financial interventions. One study reported six-month CO-validated
continuous abstinence (Papadakis 2011), the other studies
reported six-month (Curry 1998; Hughes 1991), eight-month
(Halpin 2006) and 12-month (Joyce 2008) self-reported point
prevalence abstinence. Two of the studies, Hughes 1991 and Joyce
2008, had point estimates favouring the full intervention group
but only Joyce 2008 reached statistical significance. Papadakis
2011 was underpowered to find statistically significant results. The
overall pooled estimate did not show an additional positive eLect
of full interventions on top of partial interventions on smoking
abstinence (RR 1.02, 95% CI 0.71 to 1.48, I2 = 64%, 5914 participants)
(Analysis 1.2).
Partial coverage versus another partial coverage intervention or no
intervention
Five studies reported the eLect of partial financial intervention as
compared to no financial intervention on abstinence from smoking.
Selby 2014 reported 12-month continuous abstinence and Boyle
2002 and Joyce 2008 reported 12-month point prevalence
abstinence. Two studies reported six-month point prevalence
abstinence: Hughes 1991 and Patel 2010 (CO-validated). The pooled
estimate showed a favourable eLect of financial intervention on
abstinence rates (RR 1.27, 95% CI 1.02 to 1.59, I2 = 21%, 7108
participants) (Analysis 1.3).
When assessing the eLect of financial interventions involving one
type of partial financial intervention compared with another, where
the partial intervention group with more benefits was considered
an experimental group, Curry 1998 was the only study that provided
self-reported, six-month point prevalence abstinence. There was
no statistically significant diLerence between the two intervention
strategies on abstinence rates (RR 1.20, 95% CI 0.86 to 1.68, 298
participants) (Analysis 1.4).
Number of participants making a quit attempt
Four studies evaluated the impact of full financial interventions
versus no intervention on quit attempts (Hughes 1991; SchauLler
2001; Kaper 2006; Joyce 2008). All four studies indicated a
favourable eLect of full financial intervention; this eLect was
statistically significant in SchauLler 2001 and Joyce 2008. When
the estimates were pooled there was a small positive eLect of full
benefit on the rate of quit attempts with RR of 1.11 (95% CI 1.04 to
1.17, I2 = 15%, 9065 participants) (Analysis 2.1).
Four studies assessed the impact of full versus partial financial
interventions on the rate of quit attempts (Hughes 1991; Halpin
2006; Joyce 2008; Papadakis 2011). Joyce 2008 showed a small
favourable eLect of full financial incentives on quit attempts, but
the pooled estimate did not show a statistically significant eLect
(RR 0.99, 95% CI 0.84 to 1.17, I2 = 57%, 5486 participants) (Analysis
2.2).
Five studies reported the eLect of partial financial interventions
as compared to no financial benefit on the rate of quit attempts
(Hughes 1991; Boyle 2002; Joyce 2008; Jardin 2014; Selby 2014).
All studies had confidence intervals including the line of no eLect
except for Selby 2014, which showed a statistically significant
beneficial eLect of financial intervention. The pooled estimate
marginally favoured partial financial interventions but was not
statistically significant (RR 1.13, 95% CI 0.98 to 1.31, I2 = 88%,
6944 participants) (Analysis 2.3). However, the studies showed
substantial statistical heterogeneity.
Use of smoking cessation treatment
In this section we present the pooled estimates of financial
interventions on the use of the smoking cessation treatments such
as nicotine replacement therapy (NRT), bupropion, varenicline and
behavioural interventions.
Full coverage versus no financial intervention 
Seven studies reported outcomes on the number of smokers using
smoking cessation treatment by study groups with full financial
benefit compared to those with no benefit. The overall or pooled
eLect of full financial benefit compared to no benefit on the use
of NRT, bupropion and behavioural interventions was positive
and significant in each subgroup, though we could not pool the
individual subgroups as four studies were included in multiple
subgroups (Analysis 3.1).
The studies by Hughes 1991; Dey 1999; SchauLler 2001; Kaper
2006; Twardella 2007; Joyce 2008 and Pakhale 2015 reported the
utilisation rate of NRT. In all studies full financial interventions
increased the use of NRT except for Pakhale 2015, which showed
a positive eLect on NRT utilisation but did not reach statistical
significance. The pooled estimate indicated a significantly higher
use of NRT in participants receiving full interventions with a RR of
1.79 (95% CI 1.54 to 2.09, I2 = 34%, 9455 participants) (Analysis 3.1).
Three studies reported the rate of utilisation of bupropion (Kaper
2006; Twardella 2007; Joyce 2008). All of the studies showed an
increased use of bupropion in the financial intervention group. The
pooled estimate also showed a large and significant positive eLect
of full financial intervention on the use of bupropion treatment
with a RR of 3.22 (95% CI 1.41 to 7.34, I2 = 71%, 6321 participants)
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(Analysis 3.1). However, the high heterogeneity calls for a cautious
interpretation.
Four studies reported on the utilisation of behavioural
interventions (SchauLler 2001; Kaper 2006; Twardella 2007; Joyce
2008). Kaper 2006 and Joyce 2008 indicated a positive eLect of full
financial intervention on the use of behavioural smoking cessation
therapy; SchauLler 2001 and Twardella 2007 also showed a positive
eLect on the use of therapy but the results were statistically non-
significant. Upon pooling, there was substantial heterogeneity, but
financial interventions had a statistically significant positive eLect
of on the use of behavioural therapy (RR 1.77, 95% CI 1.19 to 2.65,
I2 = 75%, 9215 participants) (Analysis 3.1). One study reported the
combined use of NRT and oral medications (Pakhale 2015), which
did not diLer significantly between research groups that received a
financial intervention and that did not (RR 1.11, 95% CI 0.73 to 1.68).
Full coverage versus partial coverage interventions
Six studies reported the impact of full compared to partial
financial interventions on the utilisation of pharmacotherapy and
behavioural support (Hughes 1991; Curry 1998; Halpin 2006; Joyce
2008; Papadakis 2011; Willemsen 2013). Because of its ITS design,
we did not include Willemsen 2013 in the subgroup analysis. As
Curry 1998 was included in multiple subgroups in this analysis,
we were unable to pool the results and report usage of each type
of therapy separately. One study showed a large and statistically
significant positive eLect of full interventions on the use of NRT
(Curry 1998). Joyce 2008 was also significant, but the remaining two
studies had similar sized smaller eLects that were not statistically
significant. There was a high level of heterogeneity in the estimate
of the pooled eLect of the four studies in regards to eLect on use
of NRT (RR 1.76, 95% CI 1.27 to 2.43, I2 = 87%, 22,380 participants)
(Analysis 3.2). Pertaining to use of behavioural interventions,
there was a significantly increased use in Curry 1998 (RR 3.95,
95% CI 3.15 to 4.95, 16,922 participants) - the only study in this
category. Willemsen 2013 measured the number of people using
behavioural therapy via the national quitline before and aSer the
introduction of a national reimbursement system. The number
of participants increased from 848 smokers enrolled in the year
before the reimbursement to 9091 smokers enrolled during the year
aSer reimbursement was instated. When the reimbursement was
discontinued, only 151 smokers enrolled in the first 18 weeks of
that year. Both Halpin 2006 and Joyce 2008 reported the utilisation
of bupropion, in which there was no statistically significant eLect
of full financial intervention as compared with partial financial
intervention with a RR of 1.42 (95% CI 0.84 to 2.41, I2 = 61%, 3700
participants) (Analysis 3.2) upon pooling. Papadakis 2011 had a
very small sample size and showed no significant results on the
use of pharmacotherapy in general (RR 1.19, 95% CI 0.70 to 2.02, 28
participants).
Partial coverage versus another partial coverage intervention or no
financial intervention
Hughes 1991; Boyle 2002; Joyce 2008; Jardin 2014 and Selby
2014 reported on the eLect of partial as compared to no
financial intervention on utilisation of pharmacotherapy. The
pooled estimate of the five studies showed a small positive
but not statistically significant eLect of the intervention on
utilisation of NRT with a RR of 1.37 (95% CI 0.99 to 1.91, I2 =
91%, 6944 participants) (Analysis 3.3). Unlike the other studies
where participants had to take action themselves to receive
pharmacotherapy, in Jardin 2014 participants in the intervention
group were sent a two-week supply of NRT by mail, which could
make the results not entirely comparable with the other studies.
If Jardin 2014 is leS out of the pooled results, the RR declines to
1.13 (95% CI 0.88 to 1.45, I2 = 86%, 6840 participants) (Analysis
3.3). Boyle 2002; Joyce 2008 and Selby 2014 presented the eLect
of partial interventions on bupropion use. Members of the group
with coverage for pharmacotherapy had a slightly higher use of
bupropion than those without (RR 1.15, 95% CI 1.03 to 1.29, I2 = 0%,
6765 participants) (Analysis 3.3).
A single study reported the eLect of a partial financial intervention
on the use of varenicline (Selby 2014). The analysis showed a
positive result on the use of varenicline (RR 1.85, CI 1.68 to 2.03,
1380 participants) (Analysis 3.3). Only the small study of Jardin
2014 reported the use of behavioural interventions, which was not
aLected by the financial intervention (RR 0.77, 95% CI 0.22 to 2.71,
104 participants) (Analysis 3.3).
Curry 1998 was the only study that reported the impact of
partial versus other partial financial interventions on the use of
pharmacotherapy and behavioural support. It did not show an
eLect on the use of NRT or behavioural interventions (RR 0.83, 95%
CI 0.68 to 1.02 and RR 0.82, 95% CI 0.61 to 1.11, 14,155 participants)
(Analysis 3.4).
The e=ect of financial interventions directed at healthcare
providers
Three studies reported the eLect of financial interventions directed
at healthcare providers (Roski 2003; Twardella 2007; An 2008).
Roski 2003 and Twardella 2007 reported outcomes on abstinence.
Neither showed statistically significant eLects. When the eLects
of financial interventions on abstinence were  pooled the results
showed that interventions targeting healthcare providers did
not aLect abstinence from smoking (RR 1.16, 95% CI 0.98 to
1.37, I2 = 0%, 2311 participants) (Analysis 4.1). In the same
two studies, financial interventions did not influence the use of
pharmacotherapy (NRT) when pooled, with a RR of 0.94 (95% CI
0.76 to 1.18, I2 = 6%, 2311 participants) (Analysis 4.2). However,
there was a statistically significant positive eLect of interventions
directed at healthcare providers on the use of behavioural support
when the three studies (Roski 2003; Twardella 2007; and An 2008)
were combined (RR 1.69, 95% CI 1.01 to 1.28, I2 = 85%, 25,820
participants)( Analysis 4.3).
The cost e=ectiveness of financial interventions
Data on the costs of the intervention were available for eight
studies (Hughes 1991; Curry 1998; SchauLler 2001; Halpin 2006;
Kaper 2006; Twardella 2007; An 2008; Joyce 2008). All studies
had interventions directed at smokers and Twardella 2007 also
included an intervention directed at physicians. As pooling of the
diLerent economic evaluations is only allowed when there is no
interaction between the setting and the eLect of the intervention
(Drummond 2015), we did not pool the results of the individual
studies. For the most part, the review authors presented smoking-
related outcomes and performed the incremental analyses . One
study calculated the costs per QALY saved (Kaper 2006).
Hughes 1991 included the following direct costs: nicotine gum,
a smoking cessation booklet and healthcare providers' time.
Participants' time was regarded as an indirect cost. The calculated
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financial gain per participant enrolled was USD 1120 with full
coverage when gum was provided free, USD 280 when gum was
provided at a cost of USD 6 per box and USD 413 when gum cost
USD 20. For the incremental analyses, we calculated the costs
per additional quitter for the diLerent comparisons. When we
compared a full incentive with a partial incentive, the costs per
additional quitter were USD 260. When we compared a full incentive
with no incentive, the costs were USD 716. A partial incentive was
not cost eLective when compared with no incentive.
Curry 1998 presented the direct costs of NRT and a behavioural
intervention programme for the diLerent coverage groups. Indirect
costs were not registered. With full coverage, the average costs
per benefit user who quit were USD 21 for users and USD 1117
for the health plan. With partial coverage, the costs per benefit
user who quit were respectively USD 326 and USD 801. We also
calculated the incremental cost-eLectiveness ratio: if full coverage
were introduced instead of partial coverage, the financial gain for
users would be USD 5316 for each benefit user who quit. For the
health plan, the costs would be USD 7646 per benefit user who quit.
SchauLler 2001 reported the total costs of NRT, the behavioural
programme and the self-help kit for the treatment group, but not
for the control group. The study authors have subsequently advised
us that the control group costs amounted to USD 29 per participant,
for the self-help kit. The average costs per quitter were USD 1495.
The costs per additional quitter for full coverage compared with no
coverage were USD 1247.
Halpin 2006 calculated the cost of treatment (self-help kit, NRT
and proactive telephone counselling). The cost per prevalent
abstinence at eight months were USD 449 per quitter in the 'drugs
only' group and USD 842 in the 'drugs and counselling' group. The
incremental cost-eLectiveness ratio we calculated was USD 731 for
each additional quitter in the 'drugs and counselling' group.
Kaper 2006 reported the costs of treatment per participant as USD
378 and USD 491 in the control group and intervention group,
respectively. The costs per additional quitter were calculated by
bootstrap replicated with a mean cost-eLectiveness ratio of USD
1453 per quitter. The mean costs per additional QALY were USD
2342. If society is willing to pay USD 12,990 for an additional 12-
month quitter, the probability that reimbursement for smoking
cessation treatment would be cost eLective was 95%.
Twardella 2007 (as reported in Salize 2009) indicated that the costs
of treating a participant ranged from USD 0 in the treatment-as-
usual group to USD 2039 in the training and incentive group, USD
6404 in the training and medication group and USD 12,821 in the
training, incentive and medication group. We used the bootstrap
replication method to calculate the costs per additional quitter,
which were USD 108 and USD 97 in the two interventions compared
to treatment as usual.
An 2008 indicated that the marginal cost for the intervention clinics
was USD 83 per additional referral and USD 300 per additional
enrollee for treatment.
In Joyce 2008, the additional cost per quitter in the intervention
groups relative to the usual-care group ranged from USD 463 to
USD 6450 per quitter. The costs escalated with increased use of
resources for treatment.
D I S C U S S I O N
We identified 14 RCTs, two controlled natural experiments
and an ITS study to answer questions on the importance
of financial interventions directed at smokers and healthcare
providers in increasing abstinence from smoking, quit attempts
by smokers, and the use of smoking cessation treatment, and
where possible to assess their cost eLectiveness. We investigated
the eLect of financial interventions by identifying comparison
subcategories between full, partial, and no financial intervention.
Full financial benefits directed at smokers provided very positive
outcomes compared to no benefits on continuous abstinence,
point prevalence abstinence, and utilisation of smoking cessation
treatment. When compared to no benefits, full financial coverage
showed a modest but positive eLect on quit attempts. Though
not consistently, full financial benefits seem to also have more
beneficial eLect than partial coverage. We detected a mixed
eLect of the diLerent levels of financial interventions with regard
to the diLerent endpoints with low to high levels of between-
studies variance (heterogeneity). There is scant evidence to
pass judgement on financial interventions directed at healthcare
providers, but the available evidence shows only limited impact on
smoking cessation.
Summary of main results
We detected a statistically significant, positive eLect of full financial
interventions targeting smokers with regard to abstinence from
smoking compared to provision of no financial intervention
at six months' follow-up or more (all abstinence measures:
RR 1.77, 95% CI 1.37 to 2.28, I2 = 33%, 9333 participants).
The eLect of full financial interventions was also extended to
favourable outcomes on the use of smoking cessation treatments:
the pooled eLect of full coverage compared with no financial
intervention on the use of smoking cessation treatments was
highly significant for each treatment type (NRT, bupropion, and
behavioural interventions). Full financial interventions had a small,
significant eLect on quit attempts (RR 1.11, CI 1.04 to 1.17, I2= 15%,
9065 participants).
When full coverage was compared to partial coverage, results
showed no significant additional eLect of full coverage on smoking
cessation or quit attempts. Pooling together results from four
trials, full coverage did increase the use of NRT when compared
with partial coverage, though the level of heterogeneity was
high (I2 = 87%). There were not enough data to investigate the
eLects of full coverage versus partial coverage on the utilisation
of bupropion or behavioural therapy. These findings could mean
that full financial interventions may have a significant eLect over
partial interventions regarding the use of treatment. However,
these findings should be interpreted with caution given the high
heterogeneity, which reflects the reality that partial interventions
could come in various shapes and combinations.
Upon pooling, we found a small positive eLect of partial financial
interventions compared to no interventions on abstinence (RR 1.27,
CI 1.02 to 1.59, I2 = 21%, 7108 participants). We did not detect an
eLect of partial financial interventions compared to other partial
or no financial interventions on attempts at quitting. There may be
an eLect of partial financial interventions when compared to no
interventions with regard to the use of pharmacotherapy. Upon the
pooling of three studies, the use of bupropion was increased (RR
1.15, 95% CI 1.03 to 1.29, I2 = 0%, 6765 participants), The use of NRT
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was also increased but pooling of the studies just failed to reach
statistical significance (RR 1.37, 95% CI 0.99 to 1.91, I2 = 91%, 6944
participants). The single study that investigated varenicline (Selby
2014) showed a positive eLect on its use (RR 1.85, 95% CI 1.68 to
2.03, 1380 participants).
Only three included studies were directed at healthcare providers,
which should be considered when interpreting the results. We
detected no eLect of healthcare provider-directed benefits on
continuous abstinence, point prevalence abstinence or on the
use of NRT. However, healthcare provider-directed interventions
compared to no intervention increased the use of behavioural
therapy (RR 1.69, 95% CI 1.01 to 2.86, I2 = 85%, 25,820 participants).
Financial benefits may induce healthcare providers to provide
behavioural-intervention support to smokers, though the high level
of heterogeneity suggests results should be interpreted carefully.
It should also be borne in mind that financial resource should not
be invested merely for increasing smoking cessation treatments
unless it can be translated into favourable quitting rates. Generally
speaking, our findings seem to support the general trend of
mixed and non-conclusive findings on healthcare provider-directed
financial interventions for improving patient outcomes (Steel 2007;
Peckham 2010; Van Herck 2010; De Bruin 2011; Flodgren 2011; Ryan
2016). 
Eight studies (Hughes 1991; Curry 1998; SchauLler 2001; Halpin
2006; Kaper 2006; Twardella 2007; An 2008; Joyce 2008) presented
data on cost eLectiveness. When full benefit was compared with
partial or no benefit, the costs per quitter ranged from USD 97 to
USD 7646.
We conclude that full financial interventions directed at smokers
when compared to no financial interventions can increase the
rate of successful quitting, quit attempts and utilisation of
pharmacotherapy in smokers.  Although the absolute diLerences
were small, the costs per additional quitter were low. We did
not detect a diLerence in eLect between full and partial financial
interventions in abstinence from smoking or increased quit
attempts, but we did find a significant diLerence in eLect between
full and partial interventions in use of NRT and behavioural
therapy. Partial versus no financial coverage showed an increase
in abstinence and quit attempts and in the use of bupropion
and varenicline. There is inadequate evidence to determine the
eLect of partial financial interventions when compared to other
partial financial interventions or no financial interventions on the
other outcomes. The conclusions need to be interpreted in light
of the reservations discussed below with regard to comparability,
classification and methodological quality.
Overall completeness and applicability of evidence
Despite the creation of relatively homogeneous subcategories
for analyses based on theoretical and practical considerations,
the studies are still heterogeneous with respect to the study
setting, motivation to participate in the study and motivation
to quit smoking. Because of such sources of heterogeneity, the
results of the meta-analysis have to be interpreted with care. The
setting of the included studies ranged from family practices and
hospital clinics in the UK, USA and Canada, to health insurance
organisations in the USA, Germany and the Netherlands. As each
country has a diLerent healthcare system, comparisons between
studies in various settings should be made in the knowledge of
these diLerences. In Dey 1999, for example, participants had to be
motivated to quit in order to participate. On entry into the study,
motivated participants received free prescriptions for nicotine
patches, and as a result, 97% of the participants in the full incentive
group used at least one prescription. Such diLerences potentially
limit the interpretability of the eLect size estimates that come out of
pooling. On the other hand, Kaper 2006 and SchauLler 2001 oLered
coverage in a general population. As participants were not enrolled
based on motivation to quit smoking, the use of NRT among
the intervention groups was 20.6% in SchauLler 2001 and 4% in
Kaper 2006. Furthermore, the interventions varied in the extent
of financial benefit, the methods of smoking cessation treatment
for which the benefit was available, the conditions for receiving
the benefit and the information concerning the new benefit.
In 12 of the 14 patient-directed financial intervention studies,
a financial benefit was available for diLerent types of smoking
cessation treatment. In two studies (Halpin 2006 and Twardella
2007), the trial arms did not enable us to examine the independent
eLect of financial interventions and hence were excluded from
the analysis.  In Twardella 2007, one of the arms involved both
patient-directed and healthcare-directed interventions, while in
Halpin 2006, special constraints were put on participants where
they were required to attend counselling before free medications
were financed.
During subgroup analyses, the main emphasis was on the level of
access to smoking cessation treatments: full, partial or no access
through financing to enable smokers to quit. Partial interventions
could refer to either pharmacotherapy or counselling only. In our
subgroup analyses no further stratification was considered for
partial interventions for smoking cessation since, in all studies,
partial interventions included pharmacotherapy only except Joyce
2008. As a result there is limited confounding by type of treatment
provided in the partial intervention group. However, future
systematic reviews, with the hope that additional studies would
accumulate, need to further stratify partial treatment benefits
highlighting the type of smoking cessation treatments covered, at
least based on behavioural interventions and pharmacotherapy.
This is due to the fact that there could be diLerences in eLect
between counselling and pharmacotherapy. It is fair to expect
that the kind of pharmacotherapy covered could also influence
the outcomes of the financing interventions. All patient-directed
studies included in this review covered NRT while nine studies
(Boyle 2002; Halpin 2006; Kaper 2006; Twardella 2007; Joyce 2008;
Papadakis 2011; Willemsen 2013; Selby 2014; Pakhale 2015) also
covered bupropion therapy and four studies additionally covered
varenicline (Papadakis 2011; Willemsen 2013; Selby 2014; Pakhale
2015).
An example of diLerent conditions for receiving a financial benefit
is related to voluntary or obligatory visits to healthcare providers.
In Kaper 2006, participants received coverage aSer a statement of
contact with a healthcare provider was sent to the health insurance
company. The use of behavioural support in Kaper 2006 is therefore
not comparable with SchauLler 2001 or Joyce 2008, in which
some or all of the participants voluntarily chose to participate in
a behavioural support intervention. There were also diLerences
in the information provided to participants about their benefit
and the extension of the benefit. In Boyle 2002, for example,
participants were not explicitly informed of the intervention, and
as a result only 30% of smokers in the treatment group knew
about the oLer of financial benefit. This may be the reason for
the statistically non-significant eLects found in Boyle 2002 when
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compared with other studies, in which participants were informed
about their new benefit. Participants’ awareness of the available
benefits could contribute significantly to an increase in the eLect
of the intervention, as it would likely increase the use of smoking
cessation treatments and hence increase the absolute number of
quitters.
The term 'full intervention' should be interpreted with caution as
it is not synonymous with optimal level of care. Furthermore, an
intervention classified as partial does not exclude the possibility
that some motivated participants may have used additional
treatment to complement those financed (e.g. SchauLler
2001). This phenomenon has also been documented by other
investigators (Hall 2002). As utilisation of smoking cessation
treatment was loosely investigated using patient and physician
reports or care provider registries, the actual utilisation rates of
the services may be lower or higher. It is also diLicult to estimate
adherence to a prescribed pharmacotherapy from the included
studies. As a result, such complexities could have influenced the
eLicacy of the interventions.
Quality of the evidence
An important limitation of the included studies was that not all
used random or concealed allocation. Twelve studies randomly
allocated the participants to the treatment or control groups, and
only five of these employed concealed allocation. Particularly in
Boyle 2002 and Curry 1998, there is the possibility of selection bias
as the studies were natural experiments. In the remaining studies,
the possibility exists that the eLect is biased. Furthermore, not
all of the studies blinded the participants, healthcare providers or
outcome assessors. In studies that assess the eLect of a financial
intervention, blinding the control group may be important, since
control participants who knew that they would not receive a
financial benefit for treatment might have felt disadvantaged and
changed their behaviour. Such a change would be a threat to
the validity of the study. We therefore could not rule out the
possibility of biased results in the unblinded studies. However, we
also acknowledge that financial interventions may be more diLicult
to blind than drug interventions.
Another methodological issue in the included studies is the low
follow-up rate, which was below 80% in most of the included
studies. This may be related to the type of intervention. If,
for example, participants are less interested in the financial
intervention when they do not want to use smoking cessation
treatments or are not motivated to quit, then the number of
dropouts could increase. In a conservative analysis, dropouts
would be considered to be continuing smokers. However, such
analyses were not performed in five studies ( Dey 1999; SchauLler
2001; Boyle 2002; Roski 2003; Twardella 2007). For this review,
we have rectified the problem by recalculating the results of
the studies using an ITT analysis that counted dropouts and
participants lost to follow-up as continuing smokers who had not
attempted to quit and not used the treatment(s) oLered.
Eight studies reported abstinence outcomes based on self-reported
smoking status, although guidelines recommend the use of
biochemically validated outcomes (West 2005). Only six studies
reported biochemically validated smoking cessation (Dey 1999;
Kaper 2006; Twardella 2007; Patel 2010; Papadakis 2011; Selby
2014), but Dey 1999 was not eligible for inclusion into the meta-
analysis for the abstinence comparison because follow-up was
terminated at 14 weeks. Fortunately, the two studies that assessed
the eLect of full financing interventions (Kaper 2006; Twardella
2007) (for which the eLect of financial interventions was significant)
reported longer-term biochemically validated abstinence rates,
and hence, have lower risk of bias in this respect. It is possible that
reliance on self-report could have introduced bias in the rest of the
studies, as participants who were benefiting from free treatment
might be more likely to give socially desirable answers than those
in the control group.
From the methodological quality assessment of the economic
evaluations, it became clear that only one of the studies reporting
on cost eLectiveness had performed a full economic evaluation
(Kaper 2006). Results were presented in terms of costs per
additional quitter or costs per person enrolled. Only one study
examined cost eLectiveness in terms of quality-adjusted life years
(QALY) saved (Kaper 2006). As a result, no comparisons can be
made with economic evaluations of other preventive healthcare
treatments.
Agreements and disagreements with other studies or
reviews
This is the only review to assess the eLects of financial interventions
directed at healthcare providers and smokers to encourage the
prescription and use of smoking cessation treatments. We found
four reviews (Bains 1998; Hamilton 2013; Cahill 2014; Cahill
2015) examining the eLects of financial interventions, but they
included studies that oLered a financial benefit for abstinence
rather than coverage of the cost of smoking cessation treatment.
Bains 1998 and Cahill 2015 discussed the use and impact of
incentives in population-based smoking cessation programmes.
Smokers participated in contests and lotteries or received financial
incentives. Cahill 2014 addressed the eLectiveness of workplace
interventions for smoking cessation. Hamilton 2013 examined the
eLect of providing financial incentives to healthcare professionals
on the provision and impact of smoking cessation interventions.
They did not find suLicient evidence to show an eLect of financial
incentives for healthcare professionals on a reduction in smoking
rates.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
In this review, covering the full cost to smokers of using smoking
cessation treatment increased the number of participants making
a quit attempt, the use of smoking cessation treatment, and
the number of successful quitters, when compared with no
financial coverage. As the majority of the studies were rated
at high or unclear risk of bias in three or more domains,
and there was variation between the settings, interventions
and participants of the included studies, the results should be
interpreted cautiously. The diLerences in self-reported abstinence
rate, number of participants making a quit attempt and use of
smoking cessation treatments were modest. However, considering
the large population of smokers worldwide and the severe health
risks of smoking, even modest eLects of financial coverage
of treatment on smoking cessation could have a substantial
eLect on public health. The results of this review suggest that
full interventions, which cover the cost of pharmacotherapy in
combination with behavioural therapy are most promising. This
review did not detect an eLect of financial interventions directed
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at healthcare providers on smoking cessation, which suggests that
financial interventions may be more beneficial when allocated to
smokers directly. However, due to the small number of studies on
financial interventions directed at healthcare providers included in
this review it may be premature to draw conclusions based on these
results.
Implications for research
More randomised controlled trials should be performed that are
comparable with the studies that are included in this review
so that future analyses can be stratified by setting, intervention
and participants. This is also true for interventions directed at
healthcare providers as only three randomised trials are available
thus far. More emphasis needs to be put on appropriate reporting
of the primary endpoint of smoking cessation, particularly
biochemical validation and long-term quitting rates (six months or
longer). More randomised trials should assess whether financial
interventions aimed at healthcare providers can aLect the
prescribing pattern and uptake of smoking cessation treatments
in addition to the smoking behaviour of their participants.
Furthermore, full economic evaluations need to be performed to
aid academics, policy makers and stakeholders alike. To assess the
financial impact of healthcare financing interventions for smoking
cessation, it is important to determine the cost eLectiveness of
these interventions more precisely. A full economic evaluation
is needed to enable comparison of cost eLectiveness with other
preventive healthcare treatments. We also recommend use of
a standard definition and classification of healthcare financing
interventions, particularly those directed at healthcare providers,
as this could facilitate future intervention research, between-
studies comparison, and rational allocation of resources.
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Methods Setting: physician network of 49 clinics in the US state of Minnesota from 2005-2006
Design: RCT
Participants 49 clinics providing adult primary care services
Interventions The 24 clinics which were randomised to the intervention group received a USD 5000 pay-for-perfor-
mance bonus if they referred 50 smokers to a national telephone quitline, and USD 25 for each addi-
tional referral. At the end of the contract period, incentive payments were made in one lump sum di-
rectly to the clinics, not to the physicians or other staL. 25 clinics were randomised to a no-intervention
control group. In both groups smokers had to express an intention to quit in the next 30 days
Outcomes The percentage of clinic's smokers referred to telephone counselling defined as the number of unique
individuals referred divided by the estimated number of smokers seen in the clinic
Notes In a post-hoc analysis, the primary outcome was calculated stratified by the level of clinic's history of
engagement with quality improvement activities: very engaged, engaged, and less engaged.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Clinics were randomly assigned to an intervention and control group.
Allocation concealment
(selection bias)
Unclear risk Differences at baseline between the characteristics of the usual care and in-
tervention clinics were statistically not significant. However, the percentage
of clinics that had a history of being very engaged in quality improvement (i.e.
the factor that modified the association between intervention and outcome)
was higher in the intervention group (21%) than in the control group (16%).
This absolute difference might have been statistically significantly different
with a larger sample size.
Blinding (performance
bias and detection bias) 
All outcomes
High risk Clinic directors and administrators were not blinded as to group assignment of
their clinic.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No attrition occurred as the measurement of the primary outcome was not
participant dependent.
Other bias Unclear risk Only a process-based outcome was reported (i.e. percentage of smokers re-
ferred to a quit line) rather than preferable targets such as smoking cessation.
An 2008 
 
 
Methods Setting: employer groups insured at the Blue Cross Blue Shield of Minnesota and Health Partners, USA,
in 1999
Design: comparative study, natural experiment
Participants Treatment group: 767. Control group: 1560
Smokers identified by postal questionnaire who were willing to participate in two postal surveys Ex-
clusions: < 100 cigarettes a lifetime, unclear health insurance status, already quit smoking or unable to
complete the survey because of illness
Av. age 46, F = 55.9%; daily smokers 91%, 46% interested in quitting over next 30 days
Boyle 2002 
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Interventions Treatment group: introduction of coverage (only with a provider's prescription) for nicotine gum, nico-
tine patch and bupropion as part of insurance benefits. Counseling was not covered.
Control group: no coverage (self-insured employer groups who chose not to offer pharmacy benefit to
employees)
Outcomes a) Self-reported continuous abstinence (no smoking for last 6 months+)
b) Self-reported quit attempt for at least 1 day
c) Utilisation of smoking cessation treatment
Notes In the treatment group only 30.3% were aware of the pharmacy benefit.
No economic evaluation was performed. Volunteer bias a potential threat. The study authors did not
provide data for ITT analysis.
Intervention categorised as partial coverage in review update 2009 because no behavioural coun-
selling was available.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Smokers were not randomly assigned to receive the benefit. Study compared
smokers in insured employer groups receiving different benefits.
Allocation concealment
(selection bias)
High risk Not directly applicable; benefit groups were not experimentally manipulated.
Response rate to baseline survey identical across conditions, measured char-
acteristics not significantly different except more people smoked within 5 min
of waking in benefit group
Blinding (performance
bias and detection bias) 
All outcomes
High risk Not applicable, participants did not know the nature of the study
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Participants were self -elected respondents to a survey so an ITT analysis was
not possible. In addition the authors did not account for 20% "unusable sam-
ple" excluded from analysis
Other bias High risk Self-reports of quitting were not biochemically validated.
Boyle 2002  (Continued)
 
 
Methods Setting: consumer-owned HMO (Group Health Cooperative of Puget Sound), Washington, USA, 1993-4
Design: comparative study, natural experiment with four coverage groups
Participants Service users (denominators for cessation rates): standard coverage (controls) n = 158. Full coverage n
= 130. Flipped coverage n = 27. Reduced coverage n = 113. Smokers covered by plans (estimates from
surveys): 6133; 2767; 1769; 6253.
Enrollees in Group Health Cooperative aged 18-64 yrs; av age 42; F = 53%
Interventions 1. Standard coverage group: 50% co-payment for the behavioural programme and full coverage of NRT
2. Full coverage group: full coverage of the behavioural programme and full coverage of NRT
3. Flipped coverage: full coverage of the behavioural programme and a 50% co-payment for NRT
4. Reduced coverage group: a 50% co-payment for the behavioural programme and a 50% co-payment
for NRT
A payment of USD 5 per prescription was not included in the coverage
Outcomes a) Self-reported 7-day PP abstinence at 6 months, for the behavioural participants only
Curry 1998 
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b) Automated data collection of the use of smoking cessation treatment, for behavioural participants
only
Notes This comparative study estimated the use of smoking services and smoking cessation using different
samples. All the participants for cessation estimation were selected among service users. Hence service
usage among all study groups was 100% for counselling, while NRT use differed from group to group.
Comparison of abstinence between full coverage and reduced coverage (50% coverage for both NRT
and the behavioural programme) after a year
Comparison of use of smoking cessation treatment, between full and flipped coverage groups, and be-
tween full and standard coverage groups after a year
An economic evaluation was performed using the third party payer perspective and users' perspective.
The costs per benefit user who quit smoking were reported.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Study compared groups of employer-based health maintenance programmes
that offered different levels of cover for smoking cessation treatment. Ran-
domisation not employed
Allocation concealment
(selection bias)
High risk Not directly applicable; benefit groups were not experimentally manipulated.
Participants were self-selected service users.
Blinding (performance
bias and detection bias) 
All outcomes
High risk Participants knew their benefit group.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk There was unbalanced missing data. Quote: "...and the overall response rate
was 81%. The numbers of respondents and response rates for the four groups
were as follows: standard coverage, 130 (82%); reduced coverage, 94 (83%);
flipped coverage, 23 (85%); and full coverage, 98 (75%)." The study authors
used an ITT analysis including non respondents.
Other bias Unclear risk Inadequate description of the different samples employed
Curry 1998  (Continued)
 
 
Methods Setting: general practices in East Lancashire, UK, in 1996
Design: RCT
Participants Treatment group n = 64. Control group n = 58
Age range 25-64 years; av. age 43; F = 56%. Participants were motivated to quit smoking; cpd > 15
Interventions Treatment group: free prescriptions for 12 weeks of nicotine patches
Control group: 12 weeks of nicotine patches at slightly reduced retail price
Outcomes a) Biochemically validated abstinence from 8-14 weeks; salivary cotinine level < 14 ng/mL, CO level < 10
ppm at 14 weeks
b) Use of smoking cessation treatment (cashing in one or more NRT prescriptions)
No economic evaluation was performed.
Notes Study not used for assessing impact on abstinence because follow-up period was less than 6 months
Risk of bias
Dey 1999 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "..were then randomly allocated by an oL-site randomisation office.."
Comment: probably done
Allocation concealment
(selection bias)
Low risk Quote: "All subjects received standardised brief counselling and were then
randomly allocated by an oL-site randomisation office.." Comment: probably
done since enrolment preceded allocation
Blinding (performance
bias and detection bias) 
All outcomes
High risk No information was provided on blinding of participants. Comment: probably
not done
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Quote: "The differential response rate is disappointing." Missing interventions
group 6/64; control group 19/58. Reasons for drop out not provided
Other bias High risk The study reported only short-term abstinence rate (3 months) in addition to
being a pilot study in nature (and hence low power as compared to the rest of
the included studies)
Dey 1999  (Continued)
 
 
Methods Setting: California HMOs, USA, in 2001
Design: RCT
Participants Control group: n = 126. Treatment group 1: n = 140. Treatment group 2: n = 127
Age range: 18-50+, F = 66%. The drugs were a 'USD 15' low cost co-payment. Counselling does not in-
volve cost sharing.
Interventions Treatment group 1: bupropion and NRT patch, inhaler and nasal spray and proactive telephone coun-
selling
Treatment group 2: if enrolled for counselling then pharmacotherapy coverage
Control: pharmacotherapy only: coverage for bupropion, and NRT patch, inhaler and nasal spray
Outcomes a) Self-reported PP abstinence at 8 months
b) Cost per additional quitter
Notes Treatment group 2 was excluded from analysis, as it added a restriction
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk The study mentioned randomisation though short of further explanation.
Comment: probably done
Allocation concealment
(selection bias)
Unclear risk No information provided
Blinding (performance
bias and detection bias) 
All outcomes
High risk Inadequate description of blinding with regard to healthcare providers, partic-
ipants or outcome assessors. Comment: probably not done
Incomplete outcome data
(attrition bias) 
Low risk ITT was conducted though there was limited characterisation of the more or
less balanced (18%) missing data.
Halpin 2006 
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All outcomes
Other bias Unclear risk No biochemical validation of quitting
Halpin 2006  (Continued)
 
 
Methods Setting: 2 rural family practices, Vermont, USA, probably 1989/1990
Design: RCT.
Participants Treatment group 1: n = 32. Treatment group 2: n = 36. Control group: n = 38
Participants aged 18+, av age 37.7 years; F = 41.9%; av 26.2 cpd; no previous use of nicotine gum
Interventions Treatment group 1: full coverage for nicotine gum
Treatment group 2: partial coverage, and nicotine gum USD 6 per box
Control group: (almost) no coverage, and nicotine gum at USD 20 per box
All participants also received brief quit smoking advice according to the 5 As (Ask, Advise, Assess, As-
sist, and Arrange)
Outcomes a) Self-reported 6 months PP abstinence (77% "observer" validated)
b) Self-reported quit attempts at 6 months c) Utilisation of smoking cessation treatment, by prescrip-
tion dates and number of unused gum pieces
An economic evaluation was performed according to a third party payer perspective. The costs were
presented per subject enrolled. The monetary benefits from smoking cessation were also calculated.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Smokers were randomly assigned.." Comment: probably done
Allocation concealment
(selection bias)
Low risk Participants were enrolled and physicians gave advice before opening sealed
envelopes. Although envelopes not specified to be numbered or opaque
judged to be low risk of bias
Blinding (performance
bias and detection bias) 
All outcomes
High risk Quote: "since the physicians knew the price each subject was paying for gum,
the physicians could have biased the study by encouraging cessation more in
the free-gum group."
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk There were 19.8% missing participants. An ITT was conducted.
Other bias Unclear risk PP was ascertained with "observer verification".
Hughes 1991 
 
 
Methods Setting: South Carolina, USA, probably 2012/2013
Design: RCT, when comparing group UNQ (unmotivated, NRT, quitline) with group UQ (unmotivated,
quitline)
Jardin 2014 
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Participants Current cigarette smokers of ≥ 10 cpd
Intervention group: n = 53, control group: n = 51, av age: intervention group: 44.6; control group: 43.9
Interventions Treatment group: 2-week supply of 14 mg nicotine patch and 4 mg lozenge plus referral to the South
Carolina state quitline
Control group: quitline referral only
Outcomes a) 24-h quit attempts
b) Use of NRT
c) Use of behavioral therapy
Notes New for 2017 update. Funding: quote: "This study was supported by the Hollings Cancer Center and Na-
tional Institute on Drug Abuse grants R01 CA141663 (PI: Cropsey) and K23 DA020482 (PI: Carpenter)".
Conflicts of interest: quote: "KMG has received funding from Merck Inc. and Supernus Pharmaceuticals
for unrelated research. KMC serves as a paid expert witness in litigation against the tobacco industry.
He also has received funding support from Pfizer Corporation to build a hospital-based cessation ser-
vice."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk The unmotivated smokers were randomised in an intervention and control
group.
Allocation concealment
(selection bias)
Unclear risk Method of concealment not described
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Method of blinding not described
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Across 628 (157 × 4) scheduled telephone calls, 96% were completed, and 92%
of participants completed all 4 telephone calls. An ITT analysis was performed.
Jardin 2014  (Continued)
 
 
Methods Cluster RCT conducted in seven states in USA
Participants 7354 elderly smokers (aged ≥ 65 years) enrolled in the Medicare Stop Smoking Program
Interventions (1) usual care (participants received smoking cessation information only), (2) reimbursement for
provider counselling, (3) reimbursement for provider counselling with pharmacotherapy (nicotine
patch or bupropion), and (4) telephone counselling quitline with pharmacotherapy (nicotine patch)
Outcomes Primary outcomes: self-reported 7 day PP of non smoking at 6- and 12-months' follow-up Secondary
outcomes: self-reported attempts to quit for at least 24 h in the first 6 and 12 months
Notes The trial was restricted to elderly smokers who had been smoking for over 40 years. Trial participants
were not randomised at individual level, but randomisation occurred at geographic locale level of pri-
Joyce 2008 
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mary care providers. Data were, however, analysed at individual level and not at cluster level (with mul-
ti-level analysis) as one would expect.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was conducted at geographic locale level of primary care
providers.
Allocation concealment
(selection bias)
High risk Benefit groups were manipulated. However there was a risk of bias because
participants were not randomised at individual level. The study reports that
"enrollees differed on race, education, income, quit attempts, and stage
of change. While statistically significant, these differences were absolutely
small."
Blinding (performance
bias and detection bias) 
All outcomes
High risk Participants and providers were not blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Attrition rates were 32.5% at 6 months and 39.4% at 12 months. For the prima-
ry analysis, these data were imputed (non-respondents counted as smokers).
It is unclear whether attrition was at random or not and whether differential
attrition occurred (attrition rates were not presented for each of the four inter-
vention groups separately).
Other bias Unclear risk Only 7-day self-reported smoking cessation used and these were not biochem-
ically validated
Joyce 2008  (Continued)
 
 
Methods Setting: smokers covered by insurance company 'De Friesland', the Netherlands, 2002
Design: RCT
Participants Treatment group: n = 632. Control group: n = 634. Participants 18+ years, av age 40 yrs, 55% men. Par-
ticipants were not required to be motivated to quit.
Interventions Intervention group: offer of reimbursement for counselling and pharmacotherapy such as bupropion
for up to 6 months post-entry
Outcomes a) Prolonged abstinence, at 12 months biochemically validated
b) PP abstinence, self-reported and biochemically validated at 12 months
c) Self-reported use of smoking cessation treatment
d) Economic evaluation performed
Notes Previously Kaper 2003. Kaper 2006 provided 12-month follow-up data plus economic evaluation, com-
pared to 6-month report in Kaper 2003
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "were randomised to the intervention or control groups using a com-
puter generated randomisation list."
Kaper 2006 
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Allocation concealment
(selection bias)
High risk Quote: "since the Dutch Institute for Public Opinion and Market Research ('TNS
NIPO') [third party] contacted the smokers, the authors did not know the par-
ticipants when performing randomisation." This is not adequate.
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "As we expected that participants in the control group might change
their behaviour because they were disappointed, we used a double ran-
domised consent design in order to blind them for the intervention group." In
addition, the authors have reported limited knowledge of treatment assign-
ment among a sub-sample of participants surveyed. The situation may not
bias the reported endpoints. Comment: participants were blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 37% of intervention and 31% of control groups lost to follow-up/dropped out
at 6 months. Only quitters followed at 12 months; 2/35 (5.7%) intervention and
3/18 (16.7%) control did not respond. An ITT analysis included all dropouts.
Other bias High risk There were limitations in outcome ascertainment. Quote: "Only 33% of the
self-reported quitters in the control group could be validated biochemically at
the end of the reimbursement period and 6-month follow-up and in the inter-
vention group this was 69%. Because of this difference between the groups,
the results of the biochemical validation should be interpreted with care."
Kaper 2006  (Continued)
 
 
Methods Setting: outpatient respirology clinic of the Ottawa Hospital in Canada, November 2011-December
2012
Design: open-label feasibility RCT study
Participants 49 respirology patients identified as smokers, who were willing to set a quit date within 1 month Av age
59.4, 49% men
Interventions Treatment group: standard care, brief counselling session, USD 110 voucher for the purchase of NRT,
bupropion or varenicline, registration to automated calling system, nurse telephone counselling for
participants who relapsed but wanted to make another quit attempt or those with low confidence
Control group: standard smoking cessation treatment including strong physician advice, information
brochure and prescription of pharmacotherapy on request
Outcomes a) Self-report smoking status 26-52 weeks
b) Use of pharmacotherapy (general)
c) Use of NRT
Notes New for 2017 update. Conflicts of interest: quote: "The authors have no financial disclosures or con-
flicts of interest to declare."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "sealed and opaque envelopes were prepared by UOHI using a comput-
er-generated allocation sequence based on stratified (according to sex) block
randomisation".
Pakhale 2015 
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Allocation concealment
(selection bias)
Low risk Quote: "sealed and opaque envelopes were prepared".
Blinding (performance
bias and detection bias) 
All outcomes
High risk Quote: "blinding of participants was not possible due to the nature of the in-
tervention"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Data were collected for 16 of 26 (62%) in the control group and 16 of 23 (70%)
in the intervention group. Loss to follow-up ws not statistically different be-
tween the control and intervention group. All participants, with the exception
of those who were deceased or had moved to an untraceable address, were in-
cluded in the analysis. Participants with missing self-reported smoking status
were considered to be smokers.
Other bias High risk Researchers were unable to collect CO samples and could therefore not veri-
fy smoking status. The decision was made to forego biochemical confirmation
which resulted in delays, and therefore outcome data were collected on dif-
ferent time points for participants, i.e. between 26 and 52 weeks. On average
these data were collected 33 weeks after baseline, with no significant differ-
ence between study groups.
Pakhale 2015  (Continued)
 
 
Methods Setting: Ottawa Hospital Stroke Prevention Clinic in Canada, probably 2010/2011
Design: cluster-RCT
Participants 28 patients who smoked ≥ five cpd, were ready to quit smoking in the next 30 days, and willing to use
pharmacotherapy. Av age 54.5, 60.7% men
Interventions Treatment group: participants received a starter kit (4-week supply) of cost-free quit-smoking medica-
tion (NRT, bupropion or varenicline) and a pre-printed renewal prescription
Control group: prescription-only usual care
Outcomes a) 26-week 7-day PP abstinence, CO validated
b) Continuous abstinence measured at 26 weeks (+- 2 weeks) after the target quit date
c) 24 h quit attempts
Notes New for 2017 update. Funding: quote: "No external funding was received for the completion of this pi-
lot study."
Competing interests: quote: "The institutions and study authors at no time received payment or ser-
vices from a third party for any aspect of the work submitted. The University of Ottawa Heart Insti-
tute has received research and education grant support from Pfizer Canada, Johnson and Johnson,
and GlaxoSmithKline. AP has served as a consultant and has received speaker honoraria from Pfizer,
Johnson and Johnson, and GlaxoSmithKline; RR has received speaker honoraria from Pfizer; DA has re-
ceived speaker honoraria from Pfizer; and DR has served as a consultant to Pfizer."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Patients were randomly assigned to one of two intervention groups.
Randomisation envelopes were prepared by a third party using a random
Papadakis 2011 
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numbers table blocked in groups of four and sealed until treatment alloca-
tion."
Allocation concealment
(selection bias)
Low risk Quote: "The research coordinator or clinic nurse specialist opened a sealed en-
velope which contained the treatment group allocation."
Blinding (performance
bias and detection bias) 
All outcomes
High risk Quote: "Due to the nature of the intervention, participants and clinicians were
not blinded to their intervention assignment." The research co-ordinator con-
ducting outcome assessment was blind to group allocation.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 5 participants were lost to follow-up (2 in intervention group and 3 in control
group). All participants were included in the ITT analysis.
Other bias Unclear risk Intervention group participants reported smoking significantly more cpd as
well as significantly greater self-efficacy (confidence) with quitting compared
to participants randomised to the control group
Papadakis 2011  (Continued)
 
 
Methods Setting: participants were recruited from Tucson, Arizona, USAand the surrounding area. The study was
conducted in an over-the-counter setting.
Design: RCT
Participants 270 self-reported smokers, aged > 18 years. (1) Free treatment group: n = 86; (2) USD 10/box, n = 89; (3)
USD 20/box, n = 93
Interventions Groups were defined according to the price at which nicotine polacrilex gum could be acquired from a
study clinic.
Treatment group 1: free nicotine polacrilex gum
Treatment group 2: nicotine polacrilex gum for USD 10/box
Treatment group 3: nicotine polacrilex gum for USD 20/box
Outcomes CO-validated PP abstinence at 26 weeks
Notes No full research report available, poster was acquired after correspondence with study author
New for 2017 update. No information on funding sources and/or competing interests
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "After obtaining the informed consent, each participant was randomly
assigned to 1 of 3 groups"
Allocation concealment
(selection bias)
Unclear risk No information on allocation concealment provided
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk No information on blinding provided
Patel 2010 
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Incomplete outcome data
(attrition bias) 
All outcomes
High risk Quote: "FiSy-five percent of subjects assigned to the $20/box arm withdrew
from the study prior to the 2-week visit compared with 34.83% of subjects as-
signed to the $10/box arm and 12 79% of subjects assigned to the $0/box arm.
Attrition rates differed significantly among the 3 groups (p < 0.001)."
Other bias Unclear risk Study was not published as a full report, data only available via research
poster
Patel 2010  (Continued)
 
 
Methods Setting: 40 clinics of a multispecialty medical group practice, in Washington DC, USA in 1999-2000
Design: Cluster-RCT with 3 groups of which 2 are included in the review
Participants Treatment group: n = 13 clinics. Control group: n = 15 clinics
A postal survey was used to identify 3436 smokers and recent ex-smokers aged ≥ 18 years with clinic
visits after the start of intervention. 2729 were surveyed by telephone after 6 months.
Interventions Treatment group: guideline dissemination to clinics, financial incentives for reaching preset clinical
performance targets
Control group: guideline dissemination
Outcomes a) Self-reported 6 months PP abstinence (i.e. no smoking previous 7 days)
b) Utilisation of smoking cessation treatment
Notes No corrections were made for clustering
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "A three-condition group randomised efficient (unbalanced) evaluation
design was employed." Comment: probably done
Allocation concealment
(selection bias)
Unclear risk Participants were identified from a postal survey of clinic attenders. No infor-
mation about baseline characteristics to judge whether participants similar
across conditions
Blinding (performance
bias and detection bias) 
All outcomes
High risk No information is provided on the blinding of assessments surveys; the study
authors; or the healthcare practice centres. In fact the study authors were
communicating the performance of the practices in general using leaflets and
charts, this may put limitation on any blinding that may have been implement-
ed.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 19.5% not reached at 6 months or excluded from analyses. No clear informa-
tion on how non-response or losses to follow-up were handled in the analysis.
The study authors only report "response rates did not differ by experimental
condition."
Other bias High risk Quote: "substantial higher incentive payments for changes in targeted clinical
practices might have threatened the generalisability of this study. The intro-
duction of practice monitoring systems by performing chart audits and the in-
troduction of the exit interviews may have had a Hawthorne effect on all clin-
ics regardless of their randomisation status." In addition, baseline comparabil-
ity was not reported.
Roski 2003 
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Methods Setting: 16 large companies offering employee health benefits from 2 California HMOs, California, USA,
in 1998
Design: RCT, pre-test post-test assessment surveys
Participants Treatment group: n = 601. Control group: n = 603
Participants aged ≥ 18 years, current smokers, smoked > 100 cigarettes in their lifetime Demographic
data not reported, but no significant differences detected between 2 study arms
Interventions Treatment group: free self-help kit, 4 free orders of nicotine gum or patches during 1 year and coverage
of a behaviour group programme
Control group: free self-help kit only
Outcomes a) Self-reported 7 day PP at 12 months b) Self-reported quit attempt (i.e. not having smoked for ≥ 1 d
over the 12 months)
c) Utilisation of smoking cessation treatment
An economic evaluation was performed according to a third party payer perspective
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "...subjects were randomly assigned to the control or treatment group."
Comment: probably done
Allocation concealment
(selection bias)
Unclear risk No information was provided on the concealment of the randomisation sched-
ule
Blinding (performance
bias and detection bias) 
All outcomes
High risk No information was provided on blinding. Comment: probably not done
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Missing data (26% control and 27% of the intervention group) were not well
addressed. An ITT was not reported, but all participants were included in the
denominators in the meta-analysis.
Other bias Unclear risk Study authors reported a high possibility of a selective group of participants.
Schau=ler 2001 
 
 
Methods Setting: 58 different ambulatory care settings across Canada, March 2009-September 2010
Design: open-label RCT
Participants Participants were adults (18–75 years) who smoked ≥ 10 cpd, were willing to set a quit date within 14 d
following screening/randomisation, had no period of abstinence > 3 months in the past year, and had
not attempted to quit smoking in the 30-day period before screening. Intervention group: n = 696, con-
trol group: n = 684, Av age intervention group: 46.5, control group: 46.7. Gender intervention group:
50.9% men, control group: 49.3% men
Interventions Treatment group: full coverage of prescribed pharmacotherapy for 26 weeks. Eligible pharmacothera-
pies were: varenicline; bupropion; and NRT patch and gum.
Selby 2014 
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Control group: no coverage
Outcomes a) Urine cotinine-confirmed 7-day PP abstinence
b) Urine cotinine-confirmed continuous abstinence at weeks 26-52
c) Having made at least 1 quit attempt
Notes New for 2017 update. Funded by Pfizer Inc. Competing interests: quote: "Pfizer sponsored the study
and recruited study sites based on various factors, including but not limited to, clinical research expe-
rience and capabilities, smoking cessation expertise/interest, and referral from peers. Data were ana-
lyzed by Pfizer and made available to the authors for interpretation and preparation of the manuscript.
PS, GB, and PO did not receive honoraria for their participation or for writing the manuscript. VR, CA,
and SR are employees of Pfizer Inc. PO, PS, and GB declare financial compensation from Pfizer Inc. for
professional services, including protocol and clinical trial materials development, initial start-up, and
end-of-study activities such as Case Report Form review, Statistical Analysis Plan review, preparation,
participation, and presentation at the Investigator Meeting, and Clinical Study Report review. No pay-
ments were made by Pfizer Inc. to PO, PS, or GB for authorship and/or authorship-related activities of
this paper. CA, SR, and VR are employees of and shareholders in Pfizer Inc."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomization was performed by the investigators using blinded lots
of computer-generated randomisation codes from the study biostatistician."
Allocation concealment
(selection bias)
Low risk Quote: "Randomization codes were mapped to SmartPayment™ cards (drug
reimbursement cards), with a distinctive colour linked to the study arm to
which the subject was randomised. The SmartPayment™ cards were enclosed
in sealed envelopes with the randomisation codes printed on the envelopes."
Blinding (performance
bias and detection bias) 
All outcomes
High risk Investigators/subjects were unblinded to study group assignment after ran-
domisation and prior to choosing a smoking cessation method(s). Regarding
blinding of outcome assessment, the risk of bias was considered low: quote:
"Confirmatory urinary cotinine measurements were collected, but investiga-
tors and patients were blinded to the results to mimic real-world practice"
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 222 (31.9%) of the intervention group and 267 (39.0%) of the control group dis-
continued the study. Reasons were reported and the reason ‘no longer will-
ing to participate’ was reported more often in the control group. The primary
analysis was ITT and involved all participants who were randomly assigned.
Selby 2014  (Continued)
 
 
Methods Setting: 82 medical practices in Germany, including 94 general practitioners, in 2006
Design: cluster-randomised trial, 2 x 2 factorial design
Participants Usual care: n = 76. TI: n = 146. TM: n = 144. TI+TM: n = 221
587 people who smoked at least 10 cpd and aged 36-75 years, F = 5.2%
Interventions TI: provision of a 2-h physician group training in SC methods and direct physician payments for every
participant not smoking 12 months after recruitment
TM: provision of the same training and direct participant reimbursement for pharmacy costs associat-
ed with NRT or bupropion treatment
Twardella 2007 
Healthcare financing systems for increasing the use of tobacco dependence treatment (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
39
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Outcomes a) Self-reported and biochemically validated PP abstinence at 12 months b) Biomedically validated CA
at 6 months
Notes GPs were not randomised. Some mistakes in calculations. TI+TM group was not used in analyses, since
effect of intervention could not be separated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomisation was performed centrally..." Comment: probably done
Allocation concealment
(selection bias)
High risk Potential for selection bias: participants recruited after practices randomised,
number of participants per practice variable. Some practices dropped out or
failed to recruit any participants. There were baseline differences; "regarding
the stage of change for smoking cessation: in arms TM and TI+TM, the propor-
tion of participants in the pre-contemplation stage - that is, participants with
no concrete intention to stop smoking - was lower, and the proportion of par-
ticipants in both the contemplation and preparation stages was higher than in
the usual care and TI arms"
Blinding (performance
bias and detection bias) 
All outcomes
High risk Quote: "Owing to the nature of the interventions, general practitioners and
participants could not be blinded to the intervention."
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Even though missing data were considered smokers there is inadequate de-
scription and no statistical analysis on differences in missing data between
groups. The authors mention ITT strategy, but did not implement it in the
analysis.
Twardella 2007  (Continued)
 
 
Methods Setting: Dutch national smoking cessation quitline 2010-2012
Design: descriptive time-series analysis
Participants Smokers signing up for proactive counselling in 2011
Interventions Starting from January 2011 and ending in December 2011, Dutch smokers were eligible for full reim-
bursement of a smoking cessation programme, consisting of behavioural treatment, preferably com-
bined with pharmacotherapy.
Outcomes The number of smokers who started a telephone counselling programme during the intervention peri-
od in 2011 compared to pre- and post-intervention in 2010 and 2012
Notes New for 2017 update. Funding sources: not stated. Competing interests: none
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not applicable
Willemsen 2013 
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Allocation concealment
(selection bias)
Unclear risk Not applicable
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Not applicable
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Not applicable
Other bias High risk There was also a media campaign when the reimbursement policy was imple-
mented, so it is not possible to disentangle the effects of the reimbursement
policy and the media campaign.
Willemsen 2013  (Continued)
Av: average (mean); CA: continuous abstinence; cpd: cigarettes per day; CO: carbon monoxide; F: female; HMO: Healthcare Maintenance
OrganisationNRT: nicotine replacement therapy; PP: point prevalence; SC: Smoking cessation; ITT: Intention to treat; TI: Training
+incentive; TM: Training+ medication; .
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Alberg 2004 Not a RCT or ITS
Amemori 2013 Outcome measure was delivery of counselling (did not meet inclusion criteria)
Amundson 2003 Not a RCT or ITS
Bailey 2016 Not a RCT or ITS
Bardach 2013 Outcome measure was delivery of counselling (did not meet inclusion criteria)
Bonevski 2016 Study protocol. Also, the effect of direct coverage of treatment was not examined separately
Chang 2008 Not a RCT or ITS
Coleman 2001 Not a RCT or ITS
Courtney 2014 Study protocol. Also, both intervention and control group received free smoking cessation treat-
ment
Cox 1990 Not a RCT or ITS
Cummings 2006 Used a quite disparate historical control. Not RCT or ITS
Curry 1991 The financial incentive was not related to the use of smoking cessation treatment
Doescher 2002 Not a RCT or ITS
Donatelle 2000 The financial incentive was not related to the use of smoking cessation treatment
Fiore 2000 Not a RCT or ITS
Fu 2016 The trial studied the effect of proactive outreach tobacco treatment
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Study Reason for exclusion
Hamilton 2013 Not a RCT or ITS
Harter 2015 Study protocol. Furthermore, the effect of a financial incentive was not assessed
Hays 1999 The effect of a financial incentive was not assessed
Hockenberry 2012 The effect of a financial incentive was not assessed
Hovell 1996 Trial was to prevent adolescent smoking, not for cessation. Russos 1999 is a secondary publication
of data from this trial
Krist 2010 Not a RCT or ITS. The free counselling intervention was not directed at smoking specifically but also
at other 'unhealthy' behaviours such alcohol drinking and overweight
Kruse 2013 Not a RCT or ITS
Land 2010 Design did not meet inclusion criteria: There were 15 time points before the intervention and 5 time
points after the intervention. But for quit attempts and quit success the number of time points was
unclear. In the results section it wa stated that “information about quit success was not asked in
every year”. In table 1, quit attempts and quit success are compared between before the interven-
tion (2003-June 2006) and after (Jan-Dec 2008); which suggests that there were only one or two
time points after the intervention for these outcomes.
Latts 2002 Not a RCT or ITS
Lave 1996 No data were available for the control group
McLeod 2015 Not a RCT or ITS
Millett 2007 Not RCT or ITS design
Moskowitz 2016 The financial incentive was not related to smoking cessation treatment
Oswald 1988 Not a RCT or ITS
Pardell 2003 The financial incentive was not related to the use of smoking cessation treatment
Park 2016 Study protocol. Furthermore, the free medication arm was confounded with additional counselling
Parnes 2002 Not a RCT or ITS
Ringen 2002 Not a RCT or ITS
Russos 1999 The financial incentive was not related to the use of smoking cessation treatment. This is a sec-
ondary publication of Hovell 1996
Shaw 2003 Data concerning the outcome measures are not yet available
Silverman 2004 Study was never published, study authors were not able to provide data
Solberg 2002 Not a RCT or ITS
Stone 2002 Not a RCT or ITS
Verbiest 2013 Outcome measure was number of prescribed medications, not participant-level use of medications
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Study Reason for exclusion
Volpp 2006 Quit and win strategy was mixed with financial interventions (did not meet inclusion criteria)
Walsh 2012 Outcome measures did not meet inclusion criteria
Weisman 2012 Not a RCT or ITS
ITS: interrupted time series; RCT: randomised controlled trial
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Efficacy and cost-effectiveness of cost-free pharmacotherapy for smoking cessation for high-risk
smokers with cerebrovascular disease
Methods Setting: the Ottawa Hospital stroke prevention clinic, Canada
Design: RCT
Participants Smokers with transient ischemic attack (TIA) or stroke attending a stroke prevention clinic and will-
ing to quit smoking
Interventions Treatment group: cost-free pharmacotherapy
Control group: prescription-only usual care group
Outcomes a) Biochemically confirmed (exhaled CO < 10 ppm) self-reported continuous abstinence from
weeks 12-52 following the target quit date.
b) Biochemically confirmed (exhaled CO < 10 ppm) self-reported continuous abstinence from
weeks 12-26 following the target quit date
c) Cost-effectiveness of providing cost-free pharmacotherapy for smoking cessation versus a pre-
scription only
Starting date December 2009
Contact information Dr Robert Reid, Ottawa Heart Institute Research Corporation
Notes  
NCT00962988 
 
 
Trial name or title Implementing tobacco use treatment guidelines in dental public health clinics
Dentistry United to Extinguish Tobacco (DUET)
Methods Setting: dental clinics in the NYC metropolitan area, USA
Design: cluster-RCT
Participants a) Clinics are included if they are located within the NYC metropolitan area and employ at least 3
FTE dentists.
b) Providers are included if they practice full-time or part-time at one of the study clinics.
Ostro= 2014 
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c) Participants are included if they are ≥ 18 years, active smokers defined as those who report
smoking cigarettes some days, most days, or every day and have smoked in the past 7 days, have
an appointment with a dentist or hygienist, NYS resident, speak English, Spanish, Chinese or Russ-
ian, and are able to comply with study procedures in the opinion of the principal investigator.
Interventions Treatment group: will receive current best practices (CBP), quarterly audit and performance feed-
back reports (PF), financial incentives (pay for performance, P4P) for every documented delivery of
adherence to clinical practice guidelines.
Control group: CBP + PF
Outcomes a) Patient utilisation of cessation services
b) Smoking abstinence
c) Cost analysis
Starting date February 2013
Contact information ostroffj@mskcc.org
Notes  
Ostro= 2014  (Continued)
RCT: randomised controlled trial
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Comparison 1.   Interventions directed at individuals: abstinence from smoking
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Full versus no financial coverage 6 9333 Risk Ratio (M-H, Random, 95% CI) 1.77 [1.37, 2.28]
1.1 Continuous abstinence (at least
6 months)
2 1486 Risk Ratio (M-H, Random, 95% CI) 4.38 [1.94, 9.87]
1.2 Point prevalence abstinence 4 7847 Risk Ratio (M-H, Random, 95% CI) 1.64 [1.45, 1.86]
2 Full versus partial financial cover-
age
5 5914 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.71, 1.48]
2.1 Continuous abstinence (at least
6 months)
1 28 Risk Ratio (M-H, Random, 95% CI) 2.17 [0.50, 9.35]
2.2 Point prevalence abstinence 4 5886 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.67, 1.44]
3 Partial versus no financial cover-
age
5 7108 Risk Ratio (M-H, Random, 95% CI) 1.27 [1.02, 1.59]
3.1 Continuous abstinence (at least
6 months)
2 3707 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.81, 1.45]
3.2 Point prevalence 3 3401 Risk Ratio (M-H, Random, 95% CI) 1.49 [0.98, 2.24]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4 Partial versus another partial cov-
erage (at least 6 months CA)
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
 
 
Analysis 1.1.   Comparison 1 Interventions directed at individuals:
abstinence from smoking, Outcome 1 Full versus no financial coverage.
Study or subgroup intervention control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.1.1 Continuous abstinence (at least 6 months)  
Kaper 2006 24/632 6/634 7.34% 4.01[1.65,9.75]
Twardella 2007 13/144 1/76 1.58% 6.86[0.91,51.46]
Subtotal (95% CI) 776 710 8.92% 4.38[1.94,9.87]
Total events: 37 (intervention), 7 (control)  
Heterogeneity: Tau2=0; Chi2=0.23, df=1(P=0.63); I2=0%  
Test for overall effect: Z=3.56(P=0)  
   
1.1.2 Point prevalence abstinence  
Hughes 1991 6/32 3/38 3.64% 2.38[0.64,8.75]
Joyce 2008 738/4295 227/2230 51.53% 1.69[1.47,1.94]
Pakhale 2015 4/22 2/26 2.47% 2.36[0.48,11.7]
Schauffler 2001 91/601 65/603 33.45% 1.4[1.04,1.89]
Subtotal (95% CI) 4950 2897 91.08% 1.64[1.45,1.86]
Total events: 839 (intervention), 297 (control)  
Heterogeneity: Tau2=0; Chi2=1.72, df=3(P=0.63); I2=0%  
Test for overall effect: Z=7.75(P<0.0001)  
   
Total (95% CI) 5726 3607 100% 1.77[1.37,2.28]
Total events: 876 (intervention), 304 (control)  
Heterogeneity: Tau2=0.03; Chi2=7.45, df=5(P=0.19); I2=32.9%  
Test for overall effect: Z=4.34(P<0.0001)  
Test for subgroup differences: Chi2=5.47, df=1 (P=0.02), I2=81.7%  
Favours control 1000.01 100.1 1 Favours intervention
 
 
Analysis 1.2.   Comparison 1 Interventions directed at individuals:
abstinence from smoking, Outcome 2 Full versus partial financial coverage.
Study or subgroup intervention control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 Continuous abstinence (at least 6 months)  
Papadakis 2011 5/15 2/13 5.51% 2.17[0.5,9.35]
Subtotal (95% CI) 15 13 5.51% 2.17[0.5,9.35]
Total events: 5 (intervention), 2 (control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.04(P=0.3)  
   
Favours control 500.02 100.1 1 Favours intervention
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Study or subgroup intervention control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.2 Point prevalence abstinence  
Curry 1998 36/130 104/298 31.28% 0.79[0.58,1.09]
Halpin 2006 18/140 24/126 20.96% 0.68[0.38,1.18]
Hughes 1991 6/32 2/36 5.1% 3.38[0.73,15.55]
Joyce 2008 738/4295 117/829 37.15% 1.22[1.02,1.46]
Subtotal (95% CI) 4597 1289 94.49% 0.98[0.67,1.44]
Total events: 798 (intervention), 247 (control)  
Heterogeneity: Tau2=0.09; Chi2=10.17, df=3(P=0.02); I2=70.51%  
Test for overall effect: Z=0.1(P=0.92)  
   
Total (95% CI) 4612 1302 100% 1.02[0.71,1.48]
Total events: 803 (intervention), 249 (control)  
Heterogeneity: Tau2=0.09; Chi2=11.05, df=4(P=0.03); I2=63.81%  
Test for overall effect: Z=0.12(P=0.9)  
Test for subgroup differences: Chi2=1.06, df=1 (P=0.3), I2=5.42%  
Favours control 500.02 100.1 1 Favours intervention
 
 
Analysis 1.3.   Comparison 1 Interventions directed at individuals:
abstinence from smoking, Outcome 3 Partial versus no financial coverage.
Study or subgroup treatment control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.1 Continuous abstinence (at least 6 months)  
Boyle 2002 64/1560 32/767 21.66% 0.98[0.65,1.49]
Selby 2014 46/696 38/684 21.58% 1.19[0.78,1.8]
Subtotal (95% CI) 2256 1451 43.24% 1.08[0.81,1.45]
Total events: 110 (treatment), 70 (control)  
Heterogeneity: Tau2=0; Chi2=0.4, df=1(P=0.53); I2=0%  
Test for overall effect: Z=0.52(P=0.6)  
   
1.3.2 Point prevalence  
Hughes 1991 2/36 3/38 1.62% 0.7[0.12,3.97]
Joyce 2008 117/829 227/2230 50.03% 1.39[1.13,1.71]
Patel 2010 9/86 7/182 5.11% 2.72[1.05,7.06]
Subtotal (95% CI) 951 2450 56.76% 1.49[0.98,2.24]
Total events: 128 (treatment), 237 (control)  
Heterogeneity: Tau2=0.04; Chi2=2.47, df=2(P=0.29); I2=18.96%  
Test for overall effect: Z=1.89(P=0.06)  
   
Total (95% CI) 3207 3901 100% 1.27[1.02,1.59]
Total events: 238 (treatment), 307 (control)  
Heterogeneity: Tau2=0.01; Chi2=5.07, df=4(P=0.28); I2=21.13%  
Test for overall effect: Z=2.14(P=0.03)  
Test for subgroup differences: Chi2=1.52, df=1 (P=0.22), I2=34.05%  
Favours control 500.02 100.1 1 Favours treatment
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Analysis 1.4.   Comparison 1 Interventions directed at individuals: abstinence from
smoking, Outcome 4 Partial versus another partial coverage (at least 6 months CA).
Study or subgroup Treatment Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Curry 1998 69/185 35/113 1.2[0.86,1.68]
Favours treatment 500.02 100.1 1 Favours control
 
 
Comparison 2.   Interventions directed at individuals: number of participants making a quit attempt for at least 24 h
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Full versus no financial coverage 4 9065 Risk Ratio (M-H, Random, 95% CI) 1.11 [1.04, 1.17]
2 Full versus partial financial coverage 4 5486 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.84, 1.17]
3 Partial versus no financial coverage 5 6944 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.98, 1.31]
 
 
Analysis 2.1.   Comparison 2 Interventions directed at individuals: number of participants
making a quit attempt for at least 24 h, Outcome 1 Full versus no financial coverage.
Study or subgroup intervention control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Hughes 1991 27/32 25/38 4.12% 1.28[0.98,1.69]
Joyce 2008 2970/4295 1431/2230 73.44% 1.08[1.04,1.12]
Kaper 2006 148/632 132/634 6.99% 1.12[0.91,1.38]
Schauffler 2001 275/601 232/603 15.45% 1.19[1.04,1.36]
   
Total (95% CI) 5560 3505 100% 1.11[1.04,1.17]
Total events: 3420 (intervention), 1820 (control)  
Heterogeneity: Tau2=0; Chi2=3.51, df=3(P=0.32); I2=14.62%  
Test for overall effect: Z=3.46(P=0)  
Favours control 20.5 1.50.7 1 Favours intervention
 
 
Analysis 2.2.   Comparison 2 Interventions directed at individuals: number of participants
making a quit attempt for at least 24 h, Outcome 2 Full versus partial financial coverage.
Study or subgroup intervention control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Halpin 2006 60/140 69/126 23.2% 0.78[0.61,1]
Hughes 1991 27/32 28/36 25.11% 1.08[0.86,1.36]
Joyce 2008 2970/4295 526/829 45.76% 1.09[1.03,1.15]
Papadakis 2011 8/15 8/13 5.93% 0.87[0.46,1.64]
   
Total (95% CI) 4482 1004 100% 0.99[0.84,1.17]
Favours control 20.5 1.50.7 1 Favours intervention
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Study or subgroup intervention control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 3065 (intervention), 631 (control)  
Heterogeneity: Tau2=0.01; Chi2=6.99, df=3(P=0.07); I2=57.07%  
Test for overall effect: Z=0.07(P=0.95)  
Favours control 20.5 1.50.7 1 Favours intervention
 
 
Analysis 2.3.   Comparison 2 Interventions directed at individuals: number of participants
making a quit attempt for at least 24 h, Outcome 3 Partial versus no financial coverage.
Study or subgroup intervention control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Boyle 2002 629/1560 290/767 25.67% 1.07[0.96,1.19]
Hughes 1991 28/36 25/38 13.75% 1.18[0.89,1.58]
Jardin 2014 17/53 8/51 3.35% 2.04[0.97,4.32]
Joyce 2008 526/829 1431/2230 28.53% 0.99[0.93,1.05]
Selby 2014 605/696 479/684 28.69% 1.24[1.17,1.31]
   
Total (95% CI) 3174 3770 100% 1.13[0.98,1.31]
Total events: 1805 (intervention), 2233 (control)  
Heterogeneity: Tau2=0.02; Chi2=33.57, df=4(P<0.0001); I2=88.09%  
Test for overall effect: Z=1.65(P=0.1)  
Favours control 20.5 1.50.7 1 Favours intervention
 
 
Comparison 3.   Interventions directed at individuals: use of smoking cessation treatment
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Full versus no financial coverage 7   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
1.1 Nicotine replacement therapy 7 9455 Risk Ratio (M-H, Random,
95% CI)
1.79 [1.54, 2.09]
1.2 Bupropion 3 6321 Risk Ratio (M-H, Random,
95% CI)
3.22 [1.41, 7.34]
1.3 Behavioural interventions 4 9215 Risk Ratio (M-H, Random,
95% CI)
1.77 [1.19, 2.65]
1.4 Pharmacotherapy, not specified 1 48 Risk Ratio (M-H, Random,
95% CI)
1.11 [0.73, 1.68]
2 Full versus partial financial coverage 5   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
2.1 Nicotine replacement therapy 4 22380 Risk Ratio (M-H, Random,
95% CI)
1.76 [1.27, 2.43]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2.2 Bupropion 2 3700 Risk Ratio (M-H, Random,
95% CI)
1.42 [0.84, 2.41]
2.3 Behavioural interventions 1 16922 Risk Ratio (M-H, Random,
95% CI)
3.95 [3.15, 4.95]
2.4 Pharmacotherapy, not specified 1 28 Risk Ratio (M-H, Random,
95% CI)
1.19 [0.70, 2.02]
3 Partial versus no financial coverage 5   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
3.1 Nicotine replacement therapy 5 6944 Risk Ratio (M-H, Random,
95% CI)
1.37 [0.99, 1.91]
3.2 Bupropion 3 6765 Risk Ratio (M-H, Random,
95% CI)
1.15 [1.03, 1.29]
3.3 Varenicline 1 1380 Risk Ratio (M-H, Random,
95% CI)
1.85 [1.68, 2.03]
3.4 Behavioural interventions 1 104 Risk Ratio (M-H, Random,
95% CI)
0.77 [0.22, 2.71]
4 Partial versus partial financial coverage 1   Risk Ratio (M-H, Random,
95% CI)
Totals not selected
4.1 Nicotine replacement therapy 1   Risk Ratio (M-H, Random,
95% CI)
0.0 [0.0, 0.0]
4.2 Behavioural interventions 1   Risk Ratio (M-H, Random,
95% CI)
0.0 [0.0, 0.0]
 
 
Analysis 3.1.   Comparison 3 Interventions directed at individuals: use of
smoking cessation treatment, Outcome 1 Full versus no financial coverage.
Study or subgroup intervention control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.1.1 Nicotine replacement therapy  
Dey 1999 62/64 28/58 18.86% 2.01[1.53,2.63]
Hughes 1991 24/32 18/38 11.35% 1.58[1.07,2.34]
Joyce 2008 1834/4295 575/2230 42.52% 1.66[1.53,1.79]
Kaper 2006 23/632 6/634 2.69% 3.85[1.58,9.38]
Pakhale 2015 9/22 8/26 3.58% 1.33[0.62,2.86]
Schauffler 2001 124/601 70/603 18.83% 1.78[1.36,2.33]
Twardella 2007 33/144 4/76 2.16% 4.35[1.6,11.83]
Subtotal (95% CI) 5790 3665 100% 1.79[1.54,2.09]
Total events: 2109 (intervention), 709 (control)  
Heterogeneity: Tau2=0.01; Chi2=9.13, df=6(P=0.17); I2=34.3%  
Favours control 200.05 50.2 1 Favours intervention
Healthcare financing systems for increasing the use of tobacco dependence treatment (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
49
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study or subgroup intervention control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=7.62(P<0.0001)  
   
3.1.2 Bupropion  
Joyce 2008 867/2605 392/2230 48.5% 1.89[1.7,2.1]
Kaper 2006 27/632 6/634 31.43% 4.51[1.88,10.86]
Twardella 2007 26/144 2/76 20.07% 6.86[1.67,28.13]
Subtotal (95% CI) 3381 2940 100% 3.22[1.41,7.34]
Total events: 920 (intervention), 400 (control)  
Heterogeneity: Tau2=0.36; Chi2=6.92, df=2(P=0.03); I2=71.08%  
Test for overall effect: Z=2.78(P=0.01)  
   
3.1.3 Behavioural interventions  
Joyce 2008 1698/4295 481/2230 41.55% 1.83[1.68,2]
Kaper 2006 32/632 7/634 15.5% 4.59[2.04,10.31]
Schauffler 2001 6/601 5/603 9.04% 1.2[0.37,3.92]
Twardella 2007 74/144 32/76 33.9% 1.22[0.9,1.66]
Subtotal (95% CI) 5672 3543 100% 1.77[1.19,2.65]
Total events: 1810 (intervention), 525 (control)  
Heterogeneity: Tau2=0.1; Chi2=11.96, df=3(P=0.01); I2=74.91%  
Test for overall effect: Z=2.8(P=0.01)  
   
3.1.4 Pharmacotherapy, not specified  
Pakhale 2015 15/22 16/26 100% 1.11[0.73,1.68]
Subtotal (95% CI) 22 26 100% 1.11[0.73,1.68]
Total events: 15 (intervention), 16 (control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.48(P=0.63)  
Test for subgroup differences: Chi2=6.82, df=1 (P=0.08), I2=55.99%  
Favours control 200.05 50.2 1 Favours intervention
 
 
Analysis 3.2.   Comparison 3 Interventions directed at individuals: use of
smoking cessation treatment, Outcome 2 Full versus partial financial coverage.
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.2.1 Nicotine replacement therapy  
Hughes 1991 24/32 21/36 24.24% 1.29[0.91,1.81]
Halpin 2006 19/140 13/126 13.92% 1.32[0.68,2.55]
Joyce 2008 1834/4295 205/829 31.52% 1.73[1.53,1.95]
Curry 1998 192/2767 374/14155 30.32% 2.63[2.22,3.11]
Subtotal (95% CI) 7234 15146 100% 1.76[1.27,2.43]
Total events: 2069 (Intervention), 613 (Control)  
Heterogeneity: Tau2=0.08; Chi2=22.55, df=3(P<0.0001); I2=86.7%  
Test for overall effect: Z=3.4(P=0)  
   
3.2.2 Bupropion  
Halpin 2006 15/140 14/126 32.27% 0.96[0.48,1.92]
Joyce 2008 867/2605 161/829 67.73% 1.71[1.48,1.99]
Subtotal (95% CI) 2745 955 100% 1.42[0.84,2.41]
Favours control 200.05 50.2 1 Favours intervention
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Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 882 (Intervention), 175 (Control)  
Heterogeneity: Tau2=0.1; Chi2=2.57, df=1(P=0.11); I2=61.05%  
Test for overall effect: Z=1.31(P=0.19)  
   
3.2.3 Behavioural interventions  
Curry 1998 129/2767 167/14155 100% 3.95[3.15,4.95]
Subtotal (95% CI) 2767 14155 100% 3.95[3.15,4.95]
Total events: 129 (Intervention), 167 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=11.91(P<0.0001)  
   
3.2.4 Pharmacotherapy, not specified  
Papadakis 2011 11/15 8/13 100% 1.19[0.7,2.02]
Subtotal (95% CI) 15 13 100% 1.19[0.7,2.02]
Total events: 11 (Intervention), 8 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.65(P=0.51)  
Favours control 200.05 50.2 1 Favours intervention
 
 
Analysis 3.3.   Comparison 3 Interventions directed at individuals: use of
smoking cessation treatment, Outcome 3 Partial versus no financial coverage.
Study or subgroup intervention control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.3.1 Nicotine replacement therapy  
Boyle 2002 412/1560 217/767 24.5% 0.93[0.81,1.07]
Hughes 1991 21/36 18/38 17.81% 1.23[0.8,1.9]
Jardin 2014 42/53 5/51 9.65% 8.08[3.48,18.79]
Joyce 2008 205/829 575/2230 24.53% 0.96[0.84,1.1]
Selby 2014 201/696 126/684 23.51% 1.57[1.29,1.91]
Subtotal (95% CI) 3174 3770 100% 1.37[0.99,1.91]
Total events: 881 (intervention), 941 (control)  
Heterogeneity: Tau2=0.11; Chi2=43.5, df=4(P<0.0001); I2=90.8%  
Test for overall effect: Z=1.87(P=0.06)  
   
3.3.2 Bupropion  
Boyle 2002 367/1560 145/767 42.96% 1.24[1.05,1.48]
Joyce 2008 161/828 392/2230 46.41% 1.11[0.94,1.3]
Selby 2014 60/696 58/684 10.63% 1.02[0.72,1.44]
Subtotal (95% CI) 3084 3681 100% 1.15[1.03,1.29]
Total events: 588 (intervention), 595 (control)  
Heterogeneity: Tau2=0; Chi2=1.51, df=2(P=0.47); I2=0%  
Test for overall effect: Z=2.48(P=0.01)  
   
3.3.3 Varenicline  
Selby 2014 558/696 297/684 100% 1.85[1.68,2.03]
Subtotal (95% CI) 696 684 100% 1.85[1.68,2.03]
Total events: 558 (intervention), 297 (control)  
Heterogeneity: Not applicable  
Favours control 200.05 50.2 1 Favours intervention
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Study or subgroup intervention control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=12.9(P<0.0001)  
   
3.3.4 Behavioural interventions  
Jardin 2014 4/53 5/51 100% 0.77[0.22,2.71]
Subtotal (95% CI) 53 51 100% 0.77[0.22,2.71]
Total events: 4 (intervention), 5 (control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.41(P=0.68)  
Favours control 200.05 50.2 1 Favours intervention
 
 
Analysis 3.4.   Comparison 3 Interventions directed at individuals: use of smoking
cessation treatment, Outcome 4 Partial versus partial financial coverage.
Study or subgroup intervention control Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
3.4.1 Nicotine replacement therapy  
Curry 1998 192/7902 182/6253 0.83[0.68,1.02]
   
3.4.2 Behavioural interventions  
Curry 1998 85/7902 82/6253 0.82[0.61,1.11]
Favours experimental 200.05 50.2 1 Favours control
 
 
Comparison 4.   Interventions directed at healthcare providers
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Abstinence from smoking 2 2311 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.98, 1.37]
1.1 Continuous abstinence (at least
6 months)
1 222 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.10, 11.30]
1.2 Point prevalence 1 2089 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.98, 1.37]
2 Use of nicotine replacement thera-
py and/or bupropion
2 2311 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.76, 1.18]
3 Use of behavioural interventions 3 25820 Risk Ratio (M-H, Random, 95% CI) 1.69 [1.01, 2.86]
 
 
Analysis 4.1.   Comparison 4 Interventions directed at healthcare providers, Outcome 1 Abstinence from smoking.
Study or subgroup intervention control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.1.1 Continuous abstinence (at least 6 months)  
Favours experimental 200.05 50.2 1 Favours control
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Study or subgroup intervention control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Twardella 2007 2/146 1/76 0.49% 1.04[0.1,11.3]
Subtotal (95% CI) 146 76 0.49% 1.04[0.1,11.3]
Total events: 2 (intervention), 1 (control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.03(P=0.97)  
   
4.1.2 Point prevalence  
Roski 2003 229/1024 205/1065 99.51% 1.16[0.98,1.37]
Subtotal (95% CI) 1024 1065 99.51% 1.16[0.98,1.37]
Total events: 229 (intervention), 205 (control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.75(P=0.08)  
   
Total (95% CI) 1170 1141 100% 1.16[0.98,1.37]
Total events: 231 (intervention), 206 (control)  
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.93); I2=0%  
Test for overall effect: Z=1.75(P=0.08)  
Test for subgroup differences: Chi2=0.01, df=1 (P=0.93), I2=0%  
Favours experimental 200.05 50.2 1 Favours control
 
 
Analysis 4.2.   Comparison 4 Interventions directed at healthcare providers,
Outcome 2 Use of nicotine replacement therapy and/or bupropion.
Study or subgroup intervention control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Roski 2003 203/1024 230/1065 93.97% 0.92[0.78,1.09]
Twardella 2007 17/146 6/76 6.03% 1.47[0.61,3.59]
   
Total (95% CI) 1170 1141 100% 0.94[0.76,1.18]
Total events: 220 (intervention), 236 (control)  
Heterogeneity: Tau2=0.01; Chi2=1.06, df=1(P=0.3); I2=5.54%  
Test for overall effect: Z=0.5(P=0.61)  
Favours control 200.05 50.2 1 Favours intervention
 
 
Analysis 4.3.   Comparison 4 Interventions directed at healthcare
providers, Outcome 3 Use of behavioural interventions.
Study or subgroup intervention control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
An 2008 384/13009 125/10500 40.65% 2.48[2.03,3.03]
Roski 2003 13/1024 11/1065 21.5% 1.23[0.55,2.73]
Twardella 2007 83/146 32/76 37.86% 1.35[1,1.82]
   
Total (95% CI) 14179 11641 100% 1.69[1.01,2.86]
Total events: 480 (intervention), 168 (control)  
Heterogeneity: Tau2=0.16; Chi2=13.22, df=2(P=0); I2=84.88%  
Test for overall effect: Z=1.98(P=0.05)  
Favours control 200.05 50.2 1 Favours intervention
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A P P E N D I C E S
Appendix 1. Specialised Register Search Strategy
Search strategy used for Specialised Register (using Cochrane Register of Studies (CRS) soSware)
#1 MeSH DESCRIPTOR Insurance Explode All
#2 MeSH DESCRIPTOR Insurance Coverage Explode All
#3 MeSH DESCRIPTOR Insurance, Health Explode All
#4 MeSH DESCRIPTOR Reimbursement Mechanisms Explode All
#5 MeSH DESCRIPTOR Insurance, Health, Reimbursement Explode All
#6 MeSH DESCRIPTOR social control policies Explode All
#7 MeSH DESCRIPTOR health care costs Explode All
#8 MeSH DESCRIPTOR Quality of Health Care Explode All
#9 MeSH DESCRIPTOR Fee-for-Service Plans Explode All
#10 MeSH DESCRIPTOR Physician Incentive Plans Explode All
#11 MeSH DESCRIPTOR Costs and Cost Analysis Explode All
#12 MeSH DESCRIPTOR Cost-Benefit Analysis Explode All
#13 health care costs
#14 health insurance
#15 coverage*:AB,TI
#16 reimburse*
#17 payment*
#18 remunerat*
#19 incentive*
#20 salary or salaries
#21 fee or fees
#22 deductible*
#23 co?insurance
#24 co?payment
#25 capita*
#26 fund?hold*
#27 prepay or prepaid
#28 financ* NEAR incentive*:AB,TI
#29 cost? NEAR (shar* or free or no):TI,AB
#30 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR
#20 OR #21 OR #22 OR #23 OR #24 OR #25  OR #26 OR #27 or #28
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Appendix 2. MEDLINE search strategy
The following topic related terms were combined with MeSH and free text terms concerning smoking and tobacco use, and with terms
to identify trials and other evaluations of healthcare eLects used by Cochrane Tobacco Addiction for regular searches of MEDLINE. (See
Specialized Register section of Tobacco Addiction Group Module). The free text term 'time series' was included in the trials identification set.
exp Insurance, Health, Reimbursement/ or exp Insurance/ or exp Insurance Coverage/ or exp Insurance, Health/ or exp Reimbursement
Mechanisms/ or exp Insurance, Health, Reimbursement/ or exp social control policies/ or exp health care costs/ or "Quality of Health Care"/
ec or exp Fee-for-Service Plans/ or exp Managed Care Programs/ or exp Physician Incentive Plans/ or exp Employee Incentive Plans/ or
(coverage or reimburs$ or target$ or payment$ or remunerat$ or incentive$ or financ$ or salar$ or fee or fees or deductible$ or coinsurance
or copayment or capita$ or cost$ or payment$ or fundhold$ or prepay$ or prepaid).mp. [mp=title, original title, abstract, name of substance
word, subject heading word]
Appendix 3. Glossary of terms
 
Term Definition
Abstinence A period of being quit, i.e. stopping the use of cigarettes or other tobacco products, may be defined
in various ways; see also: point prevalence abstinence; prolonged abstinence; continuous/sus-
tained abstinence
Biochemical verification Also called 'biochemical validation' or 'biochemical confirmation'.
A procedure for checking a tobacco user's report that he or she has not smoked or used tobacco. It
can be measured by testing levels of nicotine or cotinine or other chemicals in blood, urine, or sali-
va, or by measuring levels of carbon monoxide in exhaled breath or in blood.
Bupropion A pharmaceutical drug originally developed as an antidepressant, but now also licensed for smok-
ing cessation; trade names Zyban, Wellbutrin (when prescribed as an antidepressant)
Carbon monoxide (CO) A colourless, odourless highly poisonous gas found in tobacco smoke and in the lungs of people
who have recently smoked, or (in smaller amounts) in people who have been exposed to tobacco
smoke. May be used for biochemical verification of abstinence.
Cessation Also called 'quitting'
The goal of treatment to help people achieve abstinence from smoking or other tobacco use, also
used to describe the process of changing the behaviour
Continuous abstinence Also called 'sustained abstinence'
A measure of cessation often used in clinical trials involving avoidance of all tobacco use since the
quit day until the time the assessment is made. The definition occasionally allows for lapses. This is
the most rigorous measure of abstinence
'Cold turkey' Quitting abruptly, and/or quitting without behavioural or pharmaceutical support
Craving A very intense urge or desire [to smoke].
See: Shiffman et al 'Recommendations for the assessment of tobacco craving and withdrawal in
smoking cessation trials'
Nicotine & Tobacco Research 2004: 6(4): 599-614
Dopamine A neurotransmitter in the brain that regulates mood, attention, pleasure, reward, motivation and
movement
Efficacy Also called 'treatment effect' or 'effect size'
The difference in outcome between the experimental and control groups
Harm reduction Strategies to reduce harm caused by continued tobacco/nicotine use, such as reducing the number
of cigarettes smoked, or switching to different brands or products, e.g. potentially reduced expo-
sure products (PREPs), smokeless tobacco
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Lapse/slip Terms sometimes used for a return to tobacco use after a period of abstinence. A lapse or slip
might be defined as a puL or two on a cigarette. This may proceed to relapse, or abstinence may be
regained. Some definitions of continuous, sustained or prolonged abstinence require complete ab-
stinence, but some allow for a limited number or duration of slips. People who lapse are very likely
to relapse, but some treatments may have their effect by helping people recover from a lapse.
nAChR Neural nicotinic acetylcholine receptors
Areas in the brain that are thought to respond to nicotine, forming the basis of nicotine addiction
by stimulating the overflow of dopamine
Nicotine An alkaloid derived from tobacco, responsible for the psychoactive and addictive effects of smok-
ing.
Nicotine replacement therapy
(NRT)
A smoking cessation treatment in which nicotine from tobacco is replaced for a limited period by
pharmaceutical nicotine. This reduces the craving and withdrawal experienced during the initial
period of abstinence while users are learning to be tobacco-free. The nicotine dose can be taken
through the skin, using patches, by inhaling a spray, or by mouth using gum or lozenges.
Outcome Often used to describe the result being measured in trials that is of relevance to the review. For ex-
ample smoking cessation is the outcome used in reviews of ways to help smokers quit. The exact
outcome in terms of the definition of abstinence and the length of time that has elapsed since the
quit attempt was made may vary from trial to trial.
Pharmacotherapy A treatment using pharmaceutical drugs, e.g. NRT, bupropion
Point prevalence abstinence
(PPA)
A measure of cessation based on behaviour at a particular point in time, or during a relatively brief
specified period, e.g. 24 hours, 7 days. It may include a mixture of recent and long-term quitters.
See prolonged abstinence, continuous abstinence
Prolonged abstinence A measure of cessation which typically allows a 'grace period' following the quit date (usually of
about two weeks), to allow for slips/lapses during the first few days when the effect of treatment
may still be emerging.
See: Hughes 2003
Relapse A return to regular smoking after a period of abstinence
Secondhand smoke Also called passive smoking or environmental tobacco smoke (ETS)
A mixture of smoke exhaled by smokers and smoke released from smouldering cigarettes, cigars,
pipes, bidis, etc. The smoke mixture contains gases and particulates, including nicotine, carcino-
gens and toxins.
Self-efficacy The belief that one will be able to change one's behaviour, e.g. to quit smoking
SPC (Summary of Product
Characteristics)
Advice from the manufacturers of a drug, agreed with the relevant licensing authority, to enable
health professionals to prescribe and use the treatment safely and effectively.
Tapering A gradual decrease in dose at the end of treatment, as an alternative to abruptly stopping treat-
ment
Tar The toxic chemicals found in cigarettes. In solid form, it is the brown, tacky residue visible in a ciga-
rette filter and deposited in the lungs of smokers.
Titration A technique of dosing at low levels at the beginning of treatment, and gradually increasing to full
dose over a few days, to allow the body to get used to the drug. It is designed to limit side effects.
Varenicline A pharmaceutical drug prescribed to treat nicotine addiction; trade names Chantix and Champix
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Withdrawal A variety of behavioural, affective, cognitive and physiological symptoms, usually transient, which
occur after use of an addictive drug is reduced or stopped.
See: Shiffman 2004
  (Continued)
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Item An 2008 Curry
1998
Halpin
2006
Hughes
1991
Joyce
2008
Kaper
2006a
Salize
2009
(Twardel-
la
2007)
Schauf-
fler 2001
1. Is the study population clearly described? no no yes yes yes yes yes no
2. Are competing alternatives clearly described? yes yes yes yes yes yes yes yes
3. Is a well-defined research question posed in answerable
form?
yes yes yes yes yes yes yes yes
4. Is the economic study design appropriate to the stated
objective?
yes yes yes yes yes yes yes yes
5. Is the chosen time horizon appropriate in order to in-
clude relevant costs and consequences?
no yes yes yes no yes yes yes
6. Is the actual perspective chosen appropriate? no yes yes yes no yes yes no
7. Are all important and relevant costs for each alternative
identified?
no no no no no yes yes no
8. Are all costs measured appropriately in physical units? no no no no no yes no no
9. Are costs valued appropriately? no no no no no yes no no
10. Are all important and relevant outcomes for each alter-
native identified?
no no no no no no no no
11. Are all outcomes measured appropriately? no no yes yes no yes yes no
12. Are outcomes valued appropriately? yes yes yes yes no yes yes yes
13. Is an incremental analysis of costs and outcomes of al-
ternatives performed?
no no no no yes yes yes no
14. Are all future costs and outcomes discounted appropri-
ately?
yes yes yes yes no yes yes yes
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15. Are all important variables appropriately subjected to
sensitivity analysis?
no no no no no no yes no
16. Do the conclusions follow from the data reported? yes yes yes no no yes yes yes
17. Does the study discuss the generalisability of the results
to others settings/ patients?
Yes no yes yes no no yes yes
18. Does the article indicate that there is no potential con-
flict of interest of researchers and funders?
yes no yes no yes yes yes no
19. Are ethical and distributional issues discussed appropri-
ately?
no no no no no no no no
Total score 8 8 12 10 6 15 15 8
  (Continued)
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